Original Article
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
N Engl J Med 2003; 349:1993-2003November 20, 2003
- Abstract
Background
It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction.
Methods
In this prospective observational study, we enrolled 23,468 patients from 11 previously established cohorts from December 1999 to April 2001 and collected follow-up data until February 2002. Data were collected on infection with the human immunodeficiency virus and on risk factors for and the incidence of myocardial infarction. Relative rates were calculated with Poisson regression models. Combination antiretroviral therapy was defined as any combination regimen of antiretroviral drugs that included a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor.
Results
Over a period of 36,199 person-years, 126 patients had a myocardial infarction. The incidence of myocardial infarction increased with longer exposure to combination antiretroviral therapy (adjusted relative rate per year of exposure, 1.26 [95 percent confidence interval, 1.12 to 1.41]; P<0.001). Other factors significantly associated with myocardial infarction were older age, current or former smoking, previous cardiovascular disease, and male sex, but not a family history of coronary heart disease. A higher total serum cholesterol level, a higher triglyceride level, and the presence of diabetes were also associated with an increased incidence of myocardial infarction.
Conclusions
Combination antiretroviral therapy was independently associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use. However, the absolute risk of myocardial infarction was low and must be balanced against the marked benefits from antiretroviral treatment.
Media in This Article
Figure 1
Incidence of Myocardial Infarction According to the Duration of Exposure to Combination Antiretroviral Therapy.Table 1
Base-Line Demographic and Clinical Characteristics of the 23,468 Patients with HIV-1 Infection.Article Activity
- Article
Although the benefits of combination antiretroviral therapy have revolutionized the care of patients with human immunodeficiency virus type 1 (HIV-1) infection, increasingly severe treatment-associated metabolic side effects have been observed, among them dyslipidemia, insulin resistance, and overt diabetes mellitus, which are well-known risk factors for cardiovascular disease.1-6 These side effects may increase the risk of premature myocardial infarction, although direct evidence of such an association is inconsistently reported in the existing literature.7-19
To address this concern, and as part of an initiative by the European Agency for the Evaluation of Medicinal Products, the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study was initiated in 1999. The primary objective of the study was to determine whether exposure to combination antiretroviral therapy is independently associated with the risk of myocardial infarction.
Methods
Design
The study methods have been described previously.5 In brief, we conducted a collaborative, observational study of 11 previously established cohorts comprising 23,468 HIV-1–infected patients followed at 188 clinics in 21 countries in Europe, the United States, and Australia.
The primary study end point was myocardial infarction. The study was designed to permit the detection of a twofold difference in the incidence of myocardial infarction between two equal groups according to their exposure to combination antiretroviral therapy. A total of at least 100 new cases of myocardial infarction were required to give the study sufficient power to detect such an increase in risk (two-sided type I error, 5 percent; power, 90 percent). On the basis of preliminary data from the EuroSIDA study, the incidence of myocardial infarction in these HIV-1–infected persons was assumed to be 3.3 per 1000 person-years (Kirk O: personal communication), and hence the study had to collect at least 30,000 person-years of follow-up data before the primary objective could be examined.
Collection of Data
Patients were followed prospectively during their regular visits to outpatient clinics. Eligible patients were all under active follow-up in their individual cohorts at the time of enrollment in the study, irrespective of their antiretroviral-treatment status. Patients were consecutively enrolled in the study from clinics in each of the participating cohorts beginning in December 1999; enrollment was complete by April 2001. At enrollment and at least every eight months thereafter, standardized data-collection forms were completed at the sites to provide information about the patients' family history of coronary heart disease, their history of cardiovascular disease or diabetes, cigarette smoking, blood pressure, therapy for diabetes mellitus, lipid-lowering and antihypertensive therapy, clinical signs of lipodystrophy, and serum lipid levels (levels of total cholesterol, high-density lipoprotein [HDL] cholesterol, and triglycerides). Dyslipidemia was defined according to the U.S. National Cholesterol Education Program cutoff values for high-risk levels.20
The presence of lipodystrophy was defined subjectively and not verified objectively.21 Because information distinguishing peripheral fat loss and central fat accumulation was not collected from all the cohorts, it was not possible to perform an analysis that distinguished these phenotypes. Information on the patients' characteristics since inclusion in any of the cohorts, including information on demographic characteristics, antiretroviral therapy, surrogate markers of HIV-1 infection, and clinical course, was also collected.22 All the information collected was transformed into a standardized format and merged into a central data set. We present the data merged in July 2002 (the third merger).
Ascertainment of Outcomes
All new cases of myocardial infarction were reported to the study coordinating office for central validation and for coding according to procedures applied in the World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) Project.23-25 All events had to satisfy the criteria for a definite, possible, or unclassifiable myocardial infarction and were categorized as nonfatal (when the patient survived to 28 days after onset) or fatal. The diagnosis was based on an established algorithm25 adapted from standardized criteria that included cardiac pain, cardiac enzyme or troponin levels, electrocardiographic readings, and in cases of death, autopsy results if available. Nonfatal myocardial infarctions not associated with clinical symptoms were not included.
Quality Assurance and Governance
The training of study and medical personnel for each cohort and at each site was performed before the initiation of the study. Site monitoring was conducted annually and included a review of source documents for all the reported end points and all cases of death and an audit of the case notes for a random sample of 10 percent of the remaining patients.
The study was supervised by a steering committee with scientific and organizational independence from the financial sponsor of the study, a consortium of pharmaceutical companies that market licensed antiretroviral agents in Europe and the United States. Until the study reached the predetermined number of person-years of follow-up, members of the steering committee remained blinded to the number of end points that had occurred. An external expert from the MONICA project evaluated the documentation of primary end points, and before the event data base and main study data base were merged, an end-point committee reviewed the classification of the primary events.
Statistical Analysis
All analyses were based on calculations of the incidence rate, with base line being the time of enrollment. Only follow-up and events that occurred prospectively, after enrollment, were counted in the analyses. Follow-up ceased on the earliest of the following: the date of a primary end-point event, the date of death (if applicable), February 1, 2002, and the date six months after the patient's last contact for HIV-1–related care (defined as the most recent CD4+ cell count or HIV-1 RNA measurement, initiation of a new antiretroviral regimen, or diagnosis of a new acquired immunodeficiency syndrome [AIDS]–defining illness).
To describe the relation between the incidence of myocardial infarction and exposure to combination antiretroviral therapy, each person's follow-up was divided into a series of consecutive one-month periods. A patient's cumulative exposure to therapy at the start of each period was calculated (including the duration of treatment before enrollment in this study and during follow-up), and the result was used to assign the patient-month (and any end-point events that occurred during that month) to the appropriate exposure category. The exposure categories were as follows: no exposure or less than one year, one to two years, two to three years, three to four years, and more than four years of exposure. Follow-up data from patients with more than five years of exposure were limited. The incidence rate in each of these categories was calculated as the number of events occurring divided by the total number of patient-years in that category.
If a person discontinued therapy, his or her exposure category remained what it had been at the time of discontinuation; cumulative exposure subsequently increased only if a patient restarted therapy. No distinction was made among treatment regimens, including regimens based on protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Poisson regression models (GENMOD Procedure, SAS software, version 6.12) were used to quantify the relation between exposure to therapy and the risk of myocardial infarction, after adjustment for possible differences in the cardiovascular risk profile of patients in each exposure category. Visual assessment of the incidence rates in each category confirmed that a linear relation between exposure and incidence was a reasonable assumption. Thus, exposure was incorporated as a continuous variable in these analyses.
The primary model was adjusted for demographic factors (age, body-mass index [the weight in kilograms divided by the square of the height in meters], race, presence or absence of a family history of coronary heart disease, smoking status, and sex), mode of HIV-1 transmission, cohort, and presence or absence of preexisting cardiovascular disease before enrollment. Age was considered a time-updated, continuous variable and was recalculated at the start of each patient-month. All the other variables were treated as fixed categorical variables and took the same value for a given patient at the start of each month. Data were complete for exposure to combination antiretroviral treatment and age; however, for all the other variables, specific categories were generated for missing data to ensure that all patients were included in the analyses.
In additional exploratory analyses we assessed the influence of base-line markers of HIV-1 infection (CD4+ cell count and HIV-1 RNA level at the time of enrollment; nadir CD4+ cell count and peak HIV-1 RNA level before enrollment; and known duration of HIV-1 infection [defined according to the dates of the earliest CD4+ cell count, HIV-1 RNA level, AIDS-defining event, or treatment episode]), the presence or absence of a prior AIDS-defining event, and the presence or absence of lipodystrophy. Also analyzed was the influence of established risk factors for myocardial infarction that may potentially be influenced by combination antiretroviral therapy, including the levels of plasma lipids (total cholesterol, HDL cholesterol, and triglycerides [log2-transformed]), the presence of hypertension (defined by a systolic blood pressure of 150 mm Hg or above, a diastolic blood pressure of 100 mm Hg or above, or the use of antihypertensive agents), and the presence of diabetes mellitus. Variables that change over time (e.g., lipid levels and hypertension-related variables) were fitted separately both as fixed covariates (base-line values only) and as time-updated variables.
Sensitivity Analysis
In the primary analyses, five myocardial infarctions that occurred after the censoring date were excluded. Analyses were repeated with follow-up data censored on February 1, 2002, or on the date of a myocardial infarction or death. In additional sensitivity analyses, we considered the incidence of all end points (including eight recurrent myocardial infarctions, which occurred more than 28 days after a first primary end-point event); excluded data from patients with a prior cardiovascular event; excluded unclassifiable or possible events; and adjusted for calendar time. None of these sensitivity analyses affected the conclusions drawn from the main analyses (data not shown).
Results
Base-Line Characteristics
The study cohort included 23,468 HIV-1–infected patients; 24.1 percent were women, and the median age of the patients was 39 years. The median known duration of HIV-1 infection was 3.5 years, and 26.2 percent of the patients had previously been found to have AIDS (Table 1Table 1
Base-Line Demographic and Clinical Characteristics of the 23,468 Patients with HIV-1 Infection.). At base line, 80.8 percent of the study population had been exposed to at least one antiretroviral drug and 74.5 percent to combination antiretroviral therapy. Overall, the median cumulative exposure to combination antiretroviral therapy was 1.9 years. Because of differences in the dates when various drug classes were first marketed, the rate of exposure to protease inhibitors was substantially higher and the duration substantially longer than the rate and duration of exposure to nonnucleoside reverse transcriptase inhibitors.In this relatively young population, the prevalence of previous cardiovascular disease was only 1.5 percent (Table 2Table 2
Cardiovascular Risk Factors at Base Line.). However, many of the subjects had cardiovascular risk factors: 56.2 percent were current or previous smokers and 2.8 percent had diabetes, 7.2 percent hypertension, and 45.9 percent dyslipidemia.Follow-up
The median time between clinic visits (according to assessments of CD4+ cells) during the prospective follow-up period was three months, without consistent differences according to the duration of exposure to combination antiretroviral therapy. The total number of person-years of prospective follow-up until the first new myocardial infarction or until the censoring date for those who remained free of myocardial infarction was 36,199 (median individual follow-up time, 1.6 years [interquartile range, 1.3 to 1.9]). A total of 1909 participants (8.1 percent) had no reported clinic visits during the 12 months before February 1, 2002. During the follow-up period, 566 patients (2.4 percent) were known to have died; 36 of the deaths (6.4 percent) were due to myocardial infarction, and 26 (4.6 percent) were due to other cardiovascular events, such as stroke.
Incidence of Myocardial Infarction
A total of 126 patients had a myocardial infarction during follow-up (incidence, 3.5 events per 1000 person-years). Fifty-five percent of the myocardial infarctions were categorized as definite and 29 percent as possible; 16 percent were considered unclassifiable. One hundred fourteen of the infarctions (90 percent) occurred in men. Thirty-six of the events (29 percent) were fatal; 16 of the deaths were considered to have been caused by an unclassifiable coronary event (such as sudden death).
The incidence of myocardial infarction increased with increasing exposure to combination antiretroviral therapy (P for trend, <0.001) (Figure 1Figure 1
Incidence of Myocardial Infarction According to the Duration of Exposure to Combination Antiretroviral Therapy.). The patients with no exposure to therapy had a lower incidence of myocardial infarction than for any of the treated groups. Because the incidence increased gradually with more extended exposure, exposure time was fitted as a continuous variable in subsequent models. Fitted this way, the relative rate was 1.22 (95 percent confidence interval, 1.09 to 1.38) per additional year of exposure to combination antiretroviral therapy; it was 1.26 (95 percent confidence interval, 1.12 to 1.41) after adjustment for demographic risk factors, including age, which increased with increasing duration of therapy (Table 3Table 3
Association of Combination Antiretroviral Therapy and Other Cardiovascular Risk Factors with the Rate of Myocardial Infarction.).Other factors that also independently predicted myocardial infarction were increased age, current or past smoking, previous cardiovascular disease, and male sex, but not a family history of coronary heart disease (Table 3). The primary model also included the cohort, race, body-mass index, and mode of HIV-1 transmission, but in adjusted analyses none of these variables were independently associated with the occurrence of myocardial infarction. Intentionally, the model did not include variables such as plasma lipid concentrations, which could potentially be on the causal pathway from drug exposure to myocardial infarction.
Metabolic Disorders and Markers of HIV Disease
Individual models were developed for each of the variables listed in Table 4Table 4
The Influence of Metabolic Disorders and Markers of HIV-1 Disease on the Relative Rate of Myocardial Infarction and on the Association between the Duration of Exposure to Combination Antiretroviral Therapy and the Relative Rate of Myocardial Infarction., which also included all the variables in the primary model. At base line and during the prospective follow-up period, the following numbers of metabolic measurements were available for analysis: 82,619 for total cholesterol, 82,341 for triglycerides, and 50,241 for blood pressure. Hypertension was present or developed in 2574 patients, diabetes in 717, and lipodystrophy in 6716.At base line and during follow-up, increased total cholesterol levels, increased triglyceride levels, and the presence of diabetes were all associated with an increased risk of myocardial infarction (Table 4). The presence of hypertension at base line was not significantly associated with the risk of myocardial infarction, whereas the analysis of time-updated values did reveal an increased risk. The presence of lipodystrophy at any time was not significantly associated with the risk of myocardial infarction.
The association between combination antiretroviral therapy and the risk of myocardial infarction tended to decrease in the models that included total cholesterol or triglyceride levels, but not in those that included diabetes, hypertension, or lipodystrophy (Table 4). In addition, when total cholesterol and triglyceride levels were included in the same model, the association with therapy was not further affected (relative rate, 1.16 [95 percent confidence interval, 1.02 to 1.33]).
None of the markers of HIV-1 disease were associated with myocardial infarction in the adjusted model. Including these variables in the model did not modify the association between duration of exposure to combination antiretroviral therapy and myocardial infarction.
Discussion
Although the absolute event rate was low, combination antiretroviral therapy was associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use. This finding is plausible because combination antiretroviral therapy can cause adverse metabolic changes that are known risk factors for cardiovascular disease. However, only randomized trials might be able to prove whether the observed association reflects a causal relation. In addition, the relative increase in the risk of myocardial infarction per year cannot be extrapolated beyond the duration of follow-up in the study.
Previous studies have reached conflicting conclusions on this issue, some supporting our findings12,17,18 and others not.13-16 Most studies have been retrospective in nature and, to varying degrees, have had other limitations, including short exposure times, a small number of end points, the use of composite end points, changes in hospital admission policies over time, and lack of source verification for the end points. Two of the largest three studies failed to detect a relation,15,16 whereas the third did.18 Both of the studies that did not detect a relation were based on retrospective extraction of hospital admission codes from administrative data bases. One15 reported a surprising decrease in admission rates over time, which may be explained by changes in admission policies as well as selection and ascertainment biases. The other16 reported comparable admission rates among patients who were receiving protease inhibitors and those who were not. However, a recent update19 suggested that the rate of admission increased over time and with longer periods of exposure to protease inhibitors, although the analysis was based on few events and was not tested statistically for significance.
Our method has several advantages over those applied in prior studies. First and most important, it was a prospective study, and thus it was possible to implement extensive quality-assurance measures at the outset to ensure that all myocardial infarctions were documented according to predefined standards.23-25 Second, myocardial infarction was intentionally chosen as the primary end point, since the ascertainment of other cardiovascular events was considered to be less precise. Third, a diverse study population was achieved by enrolling patients from a variety of geographic areas, including substantial numbers of women and members of minority groups. Thus, our cohort reflects the diverse makeup of the HIV-1–infected population in industrialized countries.
Our method does have some limitations, however. We were unable to identify an appropriate cohort of HIV-1–negative persons with a similar background risk of myocardial infarction. Hence, our key objective was to assess changes in risk according to the duration of exposure to combination antiretroviral therapy. Since the median prospective follow-up time in this study was less than two years, a comparison based on the duration of exposure to combination antiretroviral therapy is essentially a comparison of patients who start therapy in different calendar years. Although adjustment for calendar time did not influence the findings, patients who started therapy in different years may have had different profiles of risk for myocardial infarction, and if so, we may not have been able to adjust for all those differences. However, we found no evidence to suggest that the duration of HIV-1 infection, the level of prior immunodeficiency, or the degree of HIV-1 RNA replication affected the association between exposure to therapy and the risk of myocardial infarction. Moreover, none of these variables had any independent effect on the risk of myocardial infarction. Finally, because of insufficient power, we are unable at the present time to examine the risk associated with individual drugs or drug classes. As the study continues, our ability to address these issues will improve.
In an attempt to elucidate a possible mechanism of the relation between combination antiretroviral therapy and myocardial infarction, we carried out preliminary analyses to examine whether the association was modified by adjusting for metabolic and physiological variables previously noted to have been influenced by antiretroviral therapy. The results suggest that the total cholesterol and triglyceride levels have a possible role. Conversely, significant contributions from diabetes, hypertension, and lipodystrophy were not identified. Further follow-up, with additional data on myocardial infarctions, will be necessary before firmer conclusions can be drawn.
Combination antiretroviral therapy substantially improves the prognosis of HIV-1–infected patients at risk for AIDS. Before the availability of such therapy, the annual mortality rate among patients with HIV-1 infection exceeded 20 percent,27 as compared with less than 2 percent in the current study. Furthermore, among the patients who died, only 6.4 percent died from myocardial infarction; progression of HIV-1–related disease was the leading cause of death. Finally, the annual rate of myocardial infarction, even among those exposed to therapy for four to six years, was less than 0.6 percent, and only a portion of the apparent excess risk could be attributed to combination antiretroviral therapy. Other known risk factors for myocardial infarction probably contributed to the occurrence of these events.26 Hence, the substantial benefits of combination antiretroviral therapy continue clearly to outweigh the increased risk of myocardial infarction associated with this therapy. However, atherosclerosis may take decades to progress to a clinically detectable degree,28 and thus further follow-up of our cohort is necessary to determine whether a substantial absolute increase in morbidity and mortality from therapy-related cardiovascular disease will emerge.29,30
Supported by the Oversight Committee for the Evaluation of Metabolic Complications of HAART, a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the Food and Drug Administration, the patient community, and all pharmaceutical companies with licensed anti-HIV drugs in the U.S. market: Abbott, Agouron, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Hoffmann–LaRoche.
Supported by a grant (CURE/97-46486) from the Health Insurance Fund Council, Amstelveen, the Netherlands, to the AIDS Therapy Evaluation Project Netherlands (ATHENA); by a grant from the Agence Nationale de Recherches sur le SIDA (Action Coordonnée no. 7, Cohortes), to the Aquitaine Cohort; by the Commonwealth Department of Health and Ageing and a grant from the Australian National Council on AIDS, Hepatitis C and Related Diseases' Clinical Trials and Research Committee, to the Australian HIV Observational Database (AHOD); by grants from the Fondo de Investigación Sanitaria (FIS 99/0887) and Funación para la Investigación y la Prevención del SIDA en España (FIPSE 3171/00), to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grants 5U01AI042170-10 and 5U01AI046362-03), to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by grants from the BIOMED 1 (CT94-1637) and BIOMED 2 (CT97-2713) programs and the fifth framework program (QLK2-2000-00773) of the European Commission and grants from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, and Roche, to the EuroSIDA study; by an unrestricted educational grant from Glaxo Wellcome, Italy, to the Italian Cohort Naive to Antiretrovirals (ICONA); and by a grant (3345-062041) from the Swiss National Science Foundation, to the Swiss HIV Cohort Study (SHCS).
Source Information
Address reprint requests to Dr. Jens D. Lundgren, DAD Coordinating Center, Copenhagen HIV Program, Section 044, Hvidovre University Hospital, 2650 Copenhagen, Denmark, or at jdl@cphiv.dk (Dr. Lundgren).
The members of the DAD study group are listed in the Appendix.
Appendix
The members of the DAD study group are as follows: Writing committee: Nina Friis-Møller (Copenhagen), Caroline A. Sabin (London), Rainer Weber (Zurich), Antonella d'Arminio Monforte (Milan), Wafaa M. El-Sadr (New York), Peter Reiss (Amsterdam), Rodolphe Thiébaut (Bordeaux), Linda Morfeldt (Stockholm), Stephane De Wit (Brussels), Christian Pradier (Nice), Gonzalo Calvo (Barcelona), Matthew G. Law (Sydney), Ole Kirk (Copenhagen), Andrew N. Phillips (London), and Jens D. Lundgren (Copenhagen); steering committee: J.D. Lundgren (chair), R. Weber (SHCS), A. d'Arminio Monforte (ICONA), G. Bartsch (CPCRA), P. Reiss (ATHENA), F. Dabis (Aquitaine), L. Morfeldt (HivBivus), S. De Wit (Brussels St. Pierre Cohort), C. Pradier (Nice Cohort), G. Calvo (BASS), M.G. Law (AHOD), O. Kirk (EuroSIDA), A.N. Phillips, F. Houyez, E. Loeliger, R. Tressler, and I. Weller; central coordination: N. Friis-Møller, C.A. Sabin, A. Sjøl (verification of primary end point), and J.D. Lundgren; data management: A. Sawitz (coordinator), M. Rickenbach, P. Pezzotti, E. Krum, R. Meester, V. Lavignolle, A. Sundström, B. Poll, E. Fontas, F. Torres, K. Petoumenos, and J. Kjær; independent advisory panel: S. Hammer, J. Neaton, and A. Sjøl.
The members of the 11 cohorts are as follows: ATHENA: Central coordination: F. de Wolf, E. van der Ven, S. Zaheri, I. Van Valkengoed, and R. Meester; participating physicians: W. Bronsveld, H. Weigel, K. Brinkman, P. Frissen, J. ten Veen, M. Hillebrand, P. van Dam, S. Schieveld, J. Mulder, E. van Gorp, P. Meenhorst, A. van Eeden, S. Danner, F. Claessen, R. Perenboom, J.K. Eeftinck Schattenkerk, M. Godfried, J. Lange, S. Lowe, J. van der Meer, F. Nellen, K. Pogany, T. van der Poll, J. Prins, P. Reiss, T. Ruys, M. van der Valk, F. Wit, C. Richter, R. van Leusen, R. Vriesendorp, F. Jeurissen, R. Kauffmann, E. Koger, B. Bravenboer, C. ten Napel, H.G. Sprenger, G. Law, R.W. ten Kate, M. Leemhuis, F. Kroon, E. Schippers, G. Schrey, S. van der Geest, A. Verbon, P. Koopmans, M. Keuter, D. Telgt, A. van der Ven, M. van der Ende, I. Gyssens, S. de Marie, J. Juttmann, C. van der Heul, M. Schneider, J. Borleffs, I. Hoepelman, C. Jaspers, A. Matute, C. Schurink, and W. Blok. Aquitaine (France): Scientific committee: R. Salamon (chair), J. Beylot, M. Dupon, M. Le Bras, J.L. Pellegrin, and J.M. Ragnaud; central coordination: F. Dabis, G. Chêne, H. Jacqmin-Gadda, R. Rhiébaut, S. Lawson-Ayayi, V. Lavignolle, E. Balestre, M.J. Blaizeau, M. Decoin, A.M. Formaggio, S. Delveaux, S. Labarerre, B. Uwamaliya, E. Vimard, L. Merchadou, G. Palmer, D. Touchard, D. Dutoit, F. Pereira, and B. Boulant; participating physicians: J. Beylot, P. Morlat, N. Bernard, M. Bonarek, F. Bonnet, B. Coadou, P. Gelie, D. Jaubert, C. Nouts, D. Lacoste, M. Dupon, H. Dutronc, G. Cipriano, S. Lafarie, I. Chossat, J.Y. Lacut, B. Leng, J.L. Pellegrin, P. Mercié, J.F. Viallard, I. Faure, P. Rispal, C. Cipriano, S. Tchamgoué, M. Le Bras, F. Djossou, D. Malvy, J.P. Pivetaud, J.M. Ragnaud, D. Chambon, C. De La Taille, T. Galperine, S. Lafarie, D. Neau, A. Ochoa, C. Beylot, M.S. Doutre, J.H. Bezian, J.F. Moreau, J.L. Taupin, C. Conri, J. Constans, P. Couzigou, L. Castera, H. Fleury, M.E. Lafon, B. Masquelier, I. Pellegrin, P. Trimoulet, F. Moreau, C. Mestre, C. Series, A. Taytard. AHOD (Australia): Central coordination: M. Law, K. Petoumenos; participating physicians: J. Anderson, J. Bal, A. Mijch, K. Watson, N. Roth, H. Wood, D. Austin, A. Gowers, D. Baker, R. McFarlane, A. Carr, D. Cooper, J. Chuah, W. Fankhauser, S. Mallal, and J. Skett. BASS (Spain): Central coordination: G. Calvo, F. Torres, and S. Mateau; participating physicians: P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch, M. Fuster, C. Codina, G. Sirera, and A. Vaqué. The Brussels St. Pierre Cohort (Belgium): N. Clumeck, S. De Wit, M. Gerard, M. Hildebrand, K. Kabeya, D. Konopnicki, M.C. Payen, B. Poll, and Y. Van Laethem. CPCRA (United States): Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr, E. Krum, G. Thompson, and D. Wentworth; participating physicians: R. Luskin-Hawk, E. Telzak, W.M. El-Sadr, D.I. Abrams, D. Cohn, N. Markowitz, R. Arduino, D. Mushatt, G. Friedland, G. Perez, E. Tedaldi, E. Fisher, F. Gordin, L.R. Crane, J. Sampson, and J. Baxter. EuroSIDA (multinational): Central coordination: O. Kirk, A. Mocroft, A.N. Phillips, and J.D. Lundgren; participating physicians: Austria — N. Vetter; Belgium — N. Clumeck, P. Hermans, and R. Colebunders; Czech Republic — L. Machala; Denmark — J. Nielsen, T. Benfield, J. Gerstoft, T. Katzenstein, B. Røge, P. Skinhøj, and C. Pedersen; France — C. Katlama, J.-P. Viard, T. Saint-Marc, P. Vanhems, and C. Pradier; Germany — M. Dietrich, C. Manegold, J. van Lunzen, V. Miller, S. Staszewski, M. Bieckel, F.D. Goebel, B. Salzberger, and J. Rockstroh; Greece — J. Kosmidis, P. Gargalianos, H. Sambatakou, J. Perdios, G. Panos, I. Karydis, and A. Filandras; Hungary — D. Banhegyi; Ireland — F. Mulcahy; Israel — I. Yust, D. Turner, S. Pollack, Z. Ben-Ishai, Z. Bentwich, and S. Maayan; Italy — S. Vella, A. Chiesi, C. Arici, R. Pristerá, F. Mazzotta, A. Gabbuti, R. Esposito, A. Bedini, A. Chirianni, E. Montesarchio, V. Vullo, P. Santopadre, P. Narciso, A. Antinori, P. Franci, M. Zaccarelli, A. Lazzarin, R. Finazzi, and A. D'Arminio Monforte; Luxembourg — R. Hemmer and T. Staub; the Netherlands — P. Reiss; Norway — J. Bruun, A. Maeland, and V. Ormaasen; Poland — B. Knysz, J. Gasiorowski, A. Horban, D. Prokopowicz, A. Boron-Kaczmarska, M. Pynka, M. Beniowski, and H. Trocha; Portugal — F. Antunes, K. Mansinho, and R. Proenca; Spain — J. González-Lahoz, B. Diaz, T. García-Benayas, L. Martin-Carbonero, V. Soriano, B. Clotet, A. Jou, J. Conejero, C. Tural, J.M. Gatell, and J.M. Miró; Sweden — A. Blaxhult, B. Heidemann, and P. Pehrson; Switzerland — B. Ledergerber, R. Weber, P. Francioli, A. Telenti, B. Hirschel, V. Soravia-Dunand, and H. Furrer; United Kingdom — M. Fisher, R. Brettle, S. Barton, A.M. Johnson, D. Mercey, C. Loveday, M.A. Johnson, A. Pinching, J. Parkin, J. Weber, and G. Scullard. HivBivus (Sweden): Central coordination: L. Morfeldt, G. Thulin, and A. Sundström; participating physicians: B. Åkerlund, K. Koppel, A. Karlsson, L. Flamholc, and C. Håkangård. ICONA (Italy): Central coordination: A. d'Arminio Monforte, P. Pezzotti; participating physicians: M. Moroni, A. d'Arminio Monforte, A. Cargnel, S. Merli, G.M. Vigevani, C. Pastecchia, A. Lazzarin, R. Novati, L. Caggese, C. Moioli, M.S. Mura, M. Mannazzu, F. Suter, C. Arici, P.E. Manconi, P. Piano, F. Mazzotta, S. Lo Caputo, A. Poggio, G. Bottari, G. Pagano, A. Alessandrini, A. Scasso, A. Vincenti, V. Abbadesse, S. Mancuso, F. Alberici, A. Ruggieri, M. Arlotti, P. Ortolani, F. De Lalla, G. Tositti, N. Piersantelli, R. Piscopo, E. Raise, S. Pasquinucci, F. Soscia, L. Tacconi, U. Tirelli, G. Nasti, D. Santoro, L. Pusterla, G. Carosi, F. Castelli, G. Cadeo, D. Vangi, G. Carnevale, D. Galloni, G. Filice, R. Bruno, A. Sinicco, M. Sciandra, P. Caramello, L. Gennero, M.L. Soranzo, M. Bonasso, G. Rizzardini, G. Migliorino, F. Chiodo, V. Colangeli, G. Magnani, M. Ursitti, F. Menichetti, C. Martinelli, R. Esposito, C. Mussini, F. Ghinelli, L. Sighinolfi, O. Coronado, T. Zauli, G. Ballardini, M. Montroni, A. Zoli, E. Petrelli, A. Cioppi, L. Ortona, A. De Luca, N. Petrosillo, P. Noto, P. Narciso, P. Salcuni, A. Antinori, P. De Longis, V. Vullo, M. Lichtner, G. Pastore, G. Minafra, A. Chirianni, L. Loiacono, M. Piazza, S. Nappa, N. Abrescia, M. De Marco, A. Colomba, T. Prestileo, C. De Stefano, A. La Gala, T. Ferraro, A. Scerbo, P. Grima, P. Tundo, E. Pizzigallo, M. D'Alessandro, B. Grisorio, and S. Ferrara. The Nice Cohort (France): Central coordination: C. Pradier, E. Fontas, and C. Caissotti: participating physicians: P. Dellamonica, L. Bentz, E. Bernard, S. Chaillou, F. De Salvador-Guillouet, J. Durant, R. Guttman, L. Heripret, V. Mondain-Miton, I. Perbost, B. Prouvost-Keller, P. Pugliese, V. Rahelinirina, P.M. Roger, and F. Vandenbos. SHCS (Switzerland): E. Bernasconi, H. Bucher, P. Bürgisser, S. Cattacin, M. Egger, P. Erb, W. Fierz, M. Fischer, M. Flepp, A. Fontana, P. Francioli (president), H.J. Furrer (chair of the clinical and laboratory committee), M. Gorgievski, H. Günthard, B. Hirschel, L. Kaiser, C. Kind, T. Klimkait, B. Ledergerber, U. Lauper, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, J.C. Piffaretti, M. Rickenbach (head of the data center), C. Rudin (chair of the Mother and Child Substudy), J. Schüpbach, R. Speck, A. Telenti, A. Trkola, P. Vernazza (chair of the scientific board), R. Weber, and S. Yerly.
- References
References
1
Carr A ,Cooper DA . Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430
CrossRef | Web of Science | Medline2
Walli R ,Herfort O ,Michl GM , et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-F173
CrossRef | Web of Science | Medline3
Vergis EN ,Paterson DL ,Wagener MM ,Swindells S ,Singh N . Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001;12:463-468
CrossRef | Web of Science | Medline4
Galli M ,Ridolfo AL ,Adorni F , et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:21-31
Web of Science | Medline5
Friis-Moller N ,Weber R ,Reiss P , et al. Cardiovascular risk factors in HIV patients -- association with antiretroviral therapy: results from the DAD study. AIDS 2003;17:1179-1193
CrossRef | Web of Science | Medline6
Carr A ,Samaras K ,Thorisdottir A ,Kaufmann GR ,Chisholm DJ ,Cooper DA . Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099
CrossRef | Web of Science | Medline7
Henry K ,Melroe H ,Huebsch J , et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328-1328
CrossRef | Web of Science | Medline8
Karmochkine M ,Raguin G . Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998;12:2499-2499
Web of Science | Medline9
Flynn TE ,Bricker LA . Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999;131:548-548
Web of Science | Medline10
Vittecoq D ,Escaut L ,Monsuez JJ . Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1959-1959
CrossRef | Web of Science | Medline11
Escaut L ,Monsuez JJ ,Chironi G , et al. Coronary artery disease in HIV infected patients. Intensive Care Med 2003;29:969-973
Web of Science | Medline12
Moore RD, Keruly JC, Lucas G. Increasing incidence of cardiovascular disease in HIV-infected persons in care. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003:132. abstract.
13
Currier J ,Taylor A ,Boyd F , et al. Coronary heart disease in HIV-infected individuals: associations with antiretroviral therapy. Antiviral Ther 2002;7:L37-L37 abstract.
Web of Science14
Coplan PM ,Nikas A ,Japour A , et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003;19:449-455
CrossRef | Web of Science | Medline15
Bozzette SA ,Ake CF ,Tam HK ,Chang SW ,Louis TA . Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710
Full Text | Web of Science | Medline16
Klein D ,Hurley LB ,Quesenberry CP Jr ,Sidney S . Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-477
CrossRef | Web of Science | Medline17
Holmberg SD ,Moorman AC ,Williamson JM , et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-1748
CrossRef | Web of Science | Medline18
Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001:657. abstract.
19
Klein D, Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003:747. abstract.
20
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science21
Carr A ,Emery S ,Law M ,Puls R ,Lundgren JD ,Powderly WG . An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-735
CrossRef | Web of Science | Medline22
1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19
23
Tunstall-Pedoe H ,Kuulasmaa K ,Amouyel P ,Arveiler D ,Rajakangas AM ,Pajak A . Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612
Web of Science | Medline24
The D:A:D Study: Data Collection on Adverse Events of Anti-HIV Drugs: study documents. (Accessed September 19, 2003, at http://www.cphiv.dk/dad/.)
25
WHO MONICA Project. MONICA manual, part IV: event registration. (Accessed September 19, 2003, at http:/www.ktl.fi/publications/monica/manual/part4/iv-1.htm.)
26
Mocroft A ,Vella S ,Benfield TL , et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-1730
CrossRef | Web of Science | Medline27
Law M ,Friis-Moller N ,Weber R , et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003;4:1-10
CrossRef | Medline28
Berenson GS ,Srinivasan SR ,Bao W ,Newman WP III ,Tracy RE ,Wattigney WA . Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998;338:1650-1656
Full Text | Web of Science | Medline29
Kuulasmaa K ,Tunstall-Pedoe H ,Dobson A , et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687
CrossRef | Web of Science | Medline30
Tunstall-Pedoe H . Myth and paradox of coronary risk and the menopause. Lancet 1998;351:1425-1427
CrossRef | Web of Science | Medline
- Citing Articles (500)
Citing Articles
1
AK Monroe, AS Dobs, X Xu, FJ Palella, LA Kingsley, WS Post, MD Witt, TT Brown. (2012) Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease. HIV Medicinen/a-n/a
CrossRef2
P.-Y. Wu, C.-C. Hung, W.-C. Liu, C.-Y. Hsieh, H.-Y. Sun, C.-L. Lu, H. Wu, K.-L. Chien. (2012) Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. Journal of Antimicrobial Chemotherapy
CrossRef3
TL Miller, W Borkowsky, LA DiMeglio, L Dooley, ME Geffner, R Hazra, EJ McFarland, AJ Mendez, K Patel, GK Siberry, RB Van Dyke, CJ Worrell, DL Jacobson, . (2012) Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Medicinen/a-n/a
CrossRef4
Absalon D. Gutierrez, Ashok Balasubramanyam. (2011) Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine
CrossRef5
B. Hasse, B. Ledergerber, H. Furrer, M. Battegay, B. Hirschel, M. Cavassini, B. Bertisch, E. Bernasconi, R. Weber, . (2011) Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. Clinical Infectious Diseases 53:11, 1130-1139
CrossRef6
L. PIROTH, I. FOURNEL, S. MAHY, Y. YAZDANPANAH, D. REY, C. RABAUD, J. P. FALLER, B. HOEN, M. FARDEHEB, C. QUANTIN, P. CHAVANET, C. BINQUET. (2011) A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients. Epidemiology and Infection 139:12, 1835-1844
CrossRef7
Oni J. Blackstock, Karen H. Wang, David A. Fiellin. (2011) State Variation in AIDS Drug Assistance Program Prescription Drug Coverage for Modifiable Cardiovascular Risk Factors. Journal of General Internal Medicine 26:12, 1426-1433
CrossRef8
Vasantha Jotwani, Yongmei Li, Carl Grunfeld, Andy I. Choi, Michael G. Shlipak. (2011) Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors. American Journal of Kidney Diseases
CrossRef9
Barry S. Peters, Anthony S. Wierzbicki, Graeme Moyle, Davaki Nair, Norbert Brockmeyer. (2011) The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial. Clinical Therapeutics
CrossRef10
Naufil Alam, Mario Cortina-Borja, Tessa Goetghebuer, Magdalena Marczynska, Alessandra Vigano, Claire Thorne. (2011) Body fat abnormality in HIV-infected children and adolescents living in Europe. JAIDS Journal of Acquired Immune Deficiency Syndromes1
CrossRef11
Michael Bohrn, Amal Mattu, Brian Browne. 2011. Chest Pain. , 1-17.
CrossRef12
María Angeles Castel, Félix Pérez-Villa, Eulalia Roig, José María Miró. (2011) Heart Transplantation in an HIV-1-Infected Patient With Ischemic Cardiomyopathy and Severe Pulmonary Hypertension. Revista Española de Cardiología (English Edition) 64:11, 1066-1067
CrossRef13
Lance T. Vernon, Denise C. Babineau, Catherine A. Demko, Michael M. Lederman, Xuelei Wang, Zahra Toossi, Aaron Weinberg, Benigno Rodriguez. (2011) A Prospective Cohort Study of Periodontal Disease Measures and Cardiovascular Disease Markers in HIV-Infected Adults. AIDS Research and Human Retroviruses 27:11, 1157-1166
CrossRef14
Mohammed Eslam, Luis F. López-Cortés, Manuel Romero-Gomez. (2011) The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. Current Opinion in HIV and AIDS 6:6, 553-558
CrossRef15
Elsayed Z. Soliman, Ronald J. Prineas, Mollie P. Roediger, Daniel A. Duprez, Franck Boccara, Christoph Boesecke, Christoph Stephan, Sally Hodder, James H. Stein, Jens D. Lundgren, James D. Neaton. (2011) Prevalence and prognostic significance of ECG abnormalities in HIV–infected patients: results from the Strategies for Management of Antiretroviral Therapy study. Journal of Electrocardiology 44:6, 779-785
CrossRef16
Christopher J. Hoffmann, Katherine L. Fielding, Victoria Johnston, Salome Charalambous, Craig Innes, Richard D. Moore, Richard E. Chaisson, Alison D. Grant, Gavin J. Churchyard. (2011) Changing Predictors of Mortality Over Time From cART Start. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 269-276
CrossRef17
María Angeles Castel, Félix Pérez-Villa, Eulalia Roig, José María Miró. (2011) Trasplante cardiaco en un paciente infectado por VIH-1 con miocardiopatía isquémica e hipertensión pulmonar grave. Revista Española de Cardiología 64:11, 1066-1067
CrossRef18
William Muronya, Esther Sanga, George Talama, Johnstone J. Kumwenda, Joep J. van Oosterhout. (2011) Cardiovascular risk factors in adult Malawians on long-term antiretroviral therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene 105:11, 644-649
CrossRef19
Fumiyo Nakagawa, Rebecca K Lodwick, Colette J Smith, Ruth Smith, Valentina Cambiano, Jens Lundgren, Valerie Delpech, Andrew N Phillips. (2011) Projected life expectancy of people with HIV according to timing of diagnosis. AIDS1
CrossRef20
F. Cortazar, M. Z. Molnar, T. Isakova, M. E. Czira, C. P. Kovesdy, D. Roth, I. Mucsi, M. Wolf. (2011) Clinical Outcomes in Kidney Transplant Recipients Receiving Long-Term Therapy With Inhibitors of the Mammalian Target of Rapamycin. American Journal of Transplantationno-no
CrossRef21
J.M. Cubero, P. Domingo, M. Sambeat, J. Ordoñez-Llanos, J. Rodriguez-Espinosa, J.L. Sánchez-Quesada, A. Pérez. (2011) Prevalence of Metabolic Syndrome Among Human Immunodeficiency Virus–Infected Subjects Is Widely Influenced by the Diagnostic Criteria. Metabolic Syndrome and Related Disorders 9:5, 345-351
CrossRef22
Sara E. Dolan Looby. (2011) Menopause-Associated Metabolic Manifestations and Symptomatology in HIV Infection: A Brief Review With Research Implications. Journal of the Association of Nurses in AIDS care
CrossRef23
J. Gutierrez, G. Ortiz. (2011) HIV/AIDS Patients with HIV Vasculopathy and VZV Vasculitis. Clinical Neuroradiology 21:3, 145-151
CrossRef24
Ngaire Caruso, Amit Chandra, Andrew Kestler. (2011) Development of Emergency Medicine in Botswana. African Journal of Emergency Medicine 1:3, 108-112
CrossRef25
C. Marzolini, D. Back, R. Weber, H. Furrer, M. Cavassini, A. Calmy, P. Vernazza, E. Bernasconi, S. Khoo, M. Battegay, L. Elzi, , M. Battegay, E. Bernasconi, J. Boni, H. C. Bucher, P. Burgisser, A. Calmy, S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi, M. Fischer, M. Flepp, A. Fontana, P. Francioli, H. Furrer, C. Fux, M. Gorgievski, H. Gunthard, H. H. Hirsch, B. Hirschel, I. Hosli, C. Kahlert, L. Kaiser, U. Karrer, C. Kind, T. Klimkait, B. Ledergerber, G. Martinetti, B. Martinez, N. Muller, D. Nadal, M. Opravil, F. Paccaud, G. Pantaleo, A. Rauch, S. Regenass, M. Rickenbach, C. Rudin, P. Schmid, D. Schultze, J. Schupbach, R. Speck, P. Taffe, P. Tarr, A. Telenti, A. Trkola, P. Vernazza, R. Weber, S. Yerly. (2011) Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy 66:9, 2107-2111
CrossRef26
NF Crum-Cianflone, D Krause, D Wessman, S Medina, J Stepenosky, C Brandt, G Boswell. (2011) Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons*. HIV Medicine 12:8, 463-471
CrossRef27
N Edwards-Jackson, SJ Kerr, HV Tieu, J Ananworanich, SM Hammer, K Ruxrungtham, P Phanuphak, A Avihingsanon, . (2011) Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Medicine 12:8, 510-515
CrossRef28
John Palios, Ignatios Ikonomidis, John Lekakis, Maria Anastasiou-Nana. (2011) Atherosclerotic vascular disorders in HIV infected patients. Artery Research 5:3, 81-90
CrossRef29
Jose Ignacio Bernardino, Marta Mora, Francisco Xavier Zamora, Blanca Arribas, Maria Luisa Montes, Francisco Pascual-Pareja, Belen San Jose, Jose Maria Peña, Jose Ramon Arribas. (2011) Hypertension and Isolated Office Hypertension in HIV-Infected Patients Determined By Ambulatory Blood Pressure Monitoring: Prevalence and Risk Factors. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:1, 54-59
CrossRef30
(2011) The Impact of Fasting on the Interpretation of Triglyceride Levels for Predicting Myocardial Infarction Risk in HIV-Positive Individuals: The D:A:D Study. Journal of Infectious Diseases 204:4, 521-525
CrossRef31
Ching-Lan Lu, Yu-Hui Lin, Wing-Wai Wong, Hsi-Hsin Lin, Mao-Wang Ho, Ning-Chi Wang, Szu-Min Hsieh, Wang-Huei Sheng, Chien-Ching Hung, Mao-Yuan Chen. (2011) Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. Journal of Microbiology, Immunology and Infection 44:4, 258-264
CrossRef32
K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, J Lundgren, MG Law, . (2011) Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*. HIV Medicine 12:7, 412-421
CrossRef33
X Escoté, A Megia, M López-Dupla, M Miranda, S Veloso, V Alba, P Domingo, P Pardo, C Viladés, J Peraire, M Giralt, C Richart, J Vendrell, F Vidal, . (2011) A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy. HIV Medicine 12:7, 428-437
CrossRef34
Su Jin Jeong, Chang Oh Kim, Young Goo Song, Ji-hyeon Baek, Sun Bean Kim, Sung Joon Jin, Nam Su Ku, Sang Hoon Han, Jun Yong Choi, Hyun Chul Lee, June Myung Kim. (2011) Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy. Atherosclerosis
CrossRef35
R. J. Bedimo, A. O. Westfall, H. Drechsler, G. Vidiella, P. Tebas. (2011) Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era. Clinical Infectious Diseases 53:1, 84-91
CrossRef36
Madeleine Durand, Odile Sheehy, Jean-Guy Baril, Jacques Lelorier, Cécile L Tremblay. (2011) Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québecʼs Public Health Insurance Database. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:3, 245-253
CrossRef37
Arvind Venkat, Sukhjit S. Takhar. 2011. Hiv-Positive Adults on Haart. , 141-157.
CrossRef38
Matthew Grant, Rafik Samuel, Robert L. Bettiker, Byungse Suh. (2011) Antiretroviral therapy 2010 update: Current practices and controversies. Archives of Pharmacal Research 34:7, 1045-1053
CrossRef39
Angela Marzocchetti, Jessica Schwarz, Simona Di Giambenedetto, Manuela Colafigli, Laura Bracciale, Massimilliano Fabbiani, Massimo Fantoni, Enrico Trecarichi, Roberto Cauda, Andrea De Luca. (2011) The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. AIDS Research and Human Retroviruses110620065459004
CrossRef40
L. Bornard, M. Blay, P.-M. Roger, M. Raucoules-Aimé, M. Carles. (2011) Anesthésie du patient infecté par le VIH. Annales Françaises d'Anesthésie et de Réanimation 30:6, 501-511
CrossRef41
Louis H. Miller, John T. Coppola. (2011) Noninvasive Assessment of HIV-related Coronary Artery Disease. Current HIV/AIDS Reports 8:2, 114-121
CrossRef42
E.R. Feeney, P.W.G. Mallon. (2011) Insulin resistance in treated HIV infection. Best Practice & Research Clinical Endocrinology & Metabolism 25:3, 443-458
CrossRef43
Julian Falutz. (2011) Growth hormone and HIV infection: Contribution to disease manifestations and clinical implications. Best Practice & Research Clinical Endocrinology & Metabolism 25:3, 517-529
CrossRef44
Chiara Giannarelli, Robert S. Klein, Juan J. Badimon. (2011) Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis
CrossRef45
A. Cournil, S. Mercier-Deheuvels, A.-M. Dupuy, J.-P. Cristol, M.-F. Anaky, F. Rouet, P. Fassinou, P. Msellati. (2011) Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire. Journal of Tropical Pediatrics
CrossRef46
J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft, . (2011) A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine 12:5, 259-268
CrossRef47
Janet Lo. (2011) Dyslipidemia and lipid management in HIV-infected patients. Current Opinion in Endocrinology, Diabetes and Obesity 18:2, 144-147
CrossRef48
Sharon R Lewin, Christine Rouzioux. (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials?. AIDS 25:7, 885-897
CrossRef49
Marisa Tungsiripat, Dalia El-Bejjani, Nesrine Rizk, Vikram Dogra, Mary Ann O'Riordan, Allison C. Ross, Corrilynn Hileman, Norma Storer, Danielle Harrill, Grace A. McComsey. (2011) Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo. AIDS Research and Human Retroviruses 27:3, 295-302
CrossRef50
Allison C Ross, Grace A McComsey. (2011) Assessment and modification of cardiovascular disease risk in the HIV-infected individual. Future Virology 6:3, 307-320
CrossRef51
Chad J Achenbach, Stephen R Cole, Mari M Kitahata, Corey Casper, James H Willig, Michael J Mugavero, Michael S Saag. (2011) Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25:5, 691-700
CrossRef52
N Gianotti, F Visco, L Galli, B Barda, P Piatti, S Salpietro, A Bigoloni, C Vinci, S Nozza, G Gallotta, A Lazzarin, A Castagna. (2011) Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Medicine 12:2, 109-117
CrossRef53
Alexandra Mangili, Joseph F. Polak, Lien A. Quach, Jul Gerrior, Christine A. Wanke. (2011) Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 214:2, 468-473
CrossRef54
Carl J. Fichtenbaum. (2011) Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Current Infectious Disease Reports 13:1, 94-101
CrossRef55
M. Cristofaro, S. Cicalini, E. Busi Rizzi, V. Schininà, N. Petrosillo, C. Bibbolino. (2011) Ultrasonography in lesions of the carotid vessels in HIV positive patients. La radiologia medica 116:1, 61-70
CrossRef56
Mar Pujades-Rodríguez, Birgit Schramm, Leakena Som, Eric Nerrienet, Prak Narom, Ngeth Chanchhaya, Laurent Ferradini, Suna Balkan. (2011) Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Tropical Medicine & International Health 16:2, 205-213
CrossRef57
T. Neumann, K.A. Lülsdorf, P. Krings, N. Reinsch, R. Erbel. (2011) Koronare Herzerkrankung bei HIV-infizierten Personen. Herz 36:1, 18-23
CrossRef58
Roy Gulick, Timothy Wilkin. (2011) CCR5 Antagonism in HIV Treatment: Current Concepts and Future Opportunities. Annual Review of Medicine 63:1, 110301100719093
CrossRef59
Robert S. Klein. (2011) Trends Related to Aging and Co-Occurring Disorders in HIV-Infected Drug Users. Substance Use & Misuse 46:2-3, 233-244
CrossRef60
A. MacInnes, A. Lazzarin, G. Di Perri, J.G. Sierra-Madero, J. Aberg, J. Heera, N. Rajicic, J. Goodrich, H. Mayer, H. Valdez. (2011) Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial. HIV Clinical Trials 12:1, 24-36
CrossRef61
Kathy Petoumenos, Signe W. Worm. (2011) HIV infection, aging and cardiovascular disease: epidemiology and prevention. Sexual Health 8:4, 465
CrossRef62
Maria Gracia Mateo, Maria del Mar Gutiérrez, Pere Domingo. (2011) Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert Review of Endocrinology & Metabolism 6:1, 21-30
CrossRef63
William Chan, Anthony M. Dart. (2011) Vascular stiffness and aging in HIV. Sexual Health 8:4, 474
CrossRef64
Damien V. Cordery, David A. Cooper. (2011) Optimal antiretroviral therapy for aging. Sexual Health 8:4, 534
CrossRef65
Arturo J Martí-Carvajal, Mario Cruciani, Arturo J Martí-Carvajal. 2010. Pharmacological interventions for treating dyslipidemia in patients with HIV infection. .
CrossRef66
Zoraya Medeiros Barros, Ricardo Arraes de Alencar Ximenes, Demócrito Barros Miranda-Filho, Maria de Fátima Pessoa Militão de Albuquerque, Heloísa Ramos Lacerda Melo, Érico Higino Carvalho, Thais Gelenske, George Diniz, Francisco Bandeira. (2010) Comparison Between the Framingham and Prospective Cardiovascular of Münster Scores for Risk Assessment of Coronary Heart Disease in Human Immunodeficiency Virus–Positive Patients in Pernambuco, Brazil. Metabolic Syndrome and Related Disorders 8:6, 489-497
CrossRef67
Mark A. Boyd, Andrew M. Hill. (2010) Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. PharmacoEconomics 28, 17-34
CrossRef68
Joanne Reekie, Csaba Kosa, Frederik Engsig, Antonella d'Arminio Monforte, Alicja Wiercinska-Drapalo, Pere Domingo, Francisco Antunes, Nathan Clumeck, Ole Kirk, Jens D. Lundgren, Amanda Mocroft. (2010) Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 116:22, 5306-5315
CrossRef69
Phyllis C Tien, Michael F Schneider, Christopher Cox, Mardge Cohen, Roksana Karim, Jason Lazar, Mary Young, Marshall J Glesby. (2010) HIV, HAART, and lipoprotein particle concentrations in the Womenʼs Interagency HIV Study. AIDS 24:18, 2809-2817
CrossRef70
Jordan E Lake, Judith S Currier. (2010) Switching antiretroviral therapy to minimize metabolic complications. HIV Therapy 4:6, 693-711
CrossRef71
Anna Maisa, Clare Westhorpe, Julian Elliott, Anthony Jaworowski, Anna C Hearps, Anthony M Dart, Jennifer Hoy, Suzanne M Crowe. (2010) Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. HIV Therapy 4:6, 675-692
CrossRef72
Roberto Martín-Reyes, Guillermo Galeote, Raúl Moreno, Ángel Sánchez-Recalde, Esteban López De Sá, José Luis López-Sendón. (2010) Intervencionismo coronario por vía percutánea en pacientes infectados por el virus de la inmunodeficiencia humana ingresados por un síndrome coronario agudo: estudio de casos y controles. Medicina Clínica 135:15, 691-694
CrossRef73
Nina Friis-Møller, Rodolphe Thiébaut, Peter Reiss, Rainer Weber, Antonella DʼArminio Monforte, Stephane De Wit, Wafaa El-Sadr, Eric Fontas, Signe Worm, Ole Kirk, Andrew Phillips, Caroline A. Sabin, Jens D. Lundgren, Matthew G. Law. (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention & Rehabilitation 17:5, 491-501
CrossRef74
Érico Higino de Carvalho, Demócrito de Barros Miranda Filho, Ricardo Arraes de Alencar Ximenes, Maria de Fátima Pessoa Militão de Albuquerque, Heloísa Ramos Lacerda de Melo, Thais Gelenske, Zoraya de Barros Medeiros, Ulisses Montarroyos, Francisco Bandeira. (2010) Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco, Brazil. Metabolic Syndrome and Related Disorders 8:5, 403-410
CrossRef75
Erdembileg Anuurad, Andrew Bremer, Lars Berglund. (2010) HIV protease inhibitors and obesity. Current Opinion in Endocrinology, Diabetes and Obesity 17:5, 478-485
CrossRef76
Jason J Schafer, William R Short, Kathleen E Squires. (2010) Association Between Abacavir Exposure and Increased Risk for Cardiovascular Disease in Patients with Human Immunodeficiency Virus. Pharmacotherapy 30:10, 1072-1083
CrossRef77
B. Jiang, A. R. Khandelwal, L. K. Rogers, V. Y. Hebert, J. J. Kleinedler, J. H. Zavecz, W. Shi, A. W. Orr, T. R. Dugas. (2010) Antiretrovirals Induce Endothelial Dysfunction via an Oxidant-Dependent Pathway and Promote Neointimal Hyperplasia. Toxicological Sciences 117:2, 524-536
CrossRef78
Tracie L Miller, Gabriel Somarriba, E John Orav, Armando J Mendez, Daniela Neri, Natasha Schaefer, Lourdes Forster, Ronald Goldberg, Gwendolyn B Scott, Steven E Lipshultz. (2010) Biomarkers of Vascular Dysfunction in Children Infected With Human Immunodeficiency Virus-1. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 182-188
CrossRef79
Amanda Mocroft, Peter Reiss, Jacek Gasiorowski, Bruno Ledergerber, Justyna Kowalska, Antonio Chiesi, Jose Gatell, Aza Rakhmanova, Margaret Johnson, Ole Kirk, Jens Lundgren. (2010) Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 262-270
CrossRef80
John Lekakis, Ignatios Ikonomidis. (2010) Cardiovascular complications of AIDS. Current Opinion in Critical Care 16:5, 408-412
CrossRef81
D. Carey, J. Amin, M. Boyd, K. Petoumenos, S. Emery. (2010) Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 65:9, 1878-1888
CrossRef82
Joseph AC Delaney, Rebecca Scherzer, Mary L Biggs, Michael G Shliplak, Joseph F Polak, Judith S Currier, Richard A Kronmal, Christine Wanke, Peter Bacchetti, Daniel Oʼleary, Phyllis C Tien, Carl Grunfeld. (2010) Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima–media thickness. AIDS 24:14, 2201-2209
CrossRef83
Kevin Johns, Ramesh Saeedi, G.B. John Mancini, Greg Bondy. (2010) Ankle Brachial Index Screening for Occult Vascular Disease Is Not Useful in HIV-Positive Patients. AIDS Research and Human Retroviruses 26:9, 955-959
CrossRef84
F. Kearney, A. R. Moore, C. F. Donegan, J. Lambert. (2010) The ageing of HIV: implications for geriatric medicine. Age and Ageing 39:5, 536-541
CrossRef85
Lidia Gazzola, Camilla Tincati, Antonella d’Arminio Monforte. (2010) Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies. HIV Therapy 4:5, 553-565
CrossRef86
M. Aboud, A. Elgalib, L. Pomeroy, G. Panayiotakopoulos, E. Skopelitis, R. Kulasegaram, C. Dimian, F. C Lampe, A. Duncan, A. S. Wierzbicki, B. S. Peters. (2010) Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. International Journal of Clinical Practice 64:9, 1252-1259
CrossRef87
Carlos Tornero, Ana Ventura, Maricarmen Mafe. (2010) Aspirin Is Indicated for Primary Prevention of Cardiovascular Events in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 54:5, 560
CrossRef88
Giovanni Guaraldi, Stefano Zona. (2010) From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. Clinical Lipidology 5:4, 583-593
CrossRef89
Martin Potter, Adefowope Odueyungbo, Hong Yang, Sahar Saeed, Marina B Klein. (2010) Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV–HCV coinfection before and after antiretroviral therapy. AIDS 24:12, 1857-1865
CrossRef90
Jennifer E Ho, Steven G Deeks, Frederick M Hecht, Yu Xie, Amanda Schnell, Jeffrey N Martin, Peter Ganz, Priscilla Y Hsue. (2010) Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 24:12, 1897-1905
CrossRef91
Beatriz Grinsztejn, Giovanni Di Perri, William Towner, Brian Woodfall, Goedele De Smedt, Monika Peeters. (2010) A Review of the Safety and Tolerability Profile of the Next-Generation NNRTI Etravirine. AIDS Research and Human Retroviruses 26:7, 725-733
CrossRef92
Amanda Mocroft, Ole Kirk, Peter Reiss, Stephane De Wit, Dalibor Sedlacek, Marek Beniowski, Jose Gatell, Andrew N Phillips, Bruno Ledergerber, Jens D Lundgren. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24:11, 1667-1678
CrossRef93
Carl J. Fichtenbaum, Tzu-Min Yeh, Scott R. Evans, Judith A. Aberg. (2010) Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Journal of Clinical Lipidology 4:4, 279-287
CrossRef94
Amit C Achhra, Janaki Amin, Matthew G Law, Sean Emery, Jan Gerstoft, Fred M Gordin, Michael J Vjecha, James D Neaton, David A Cooper. (2010) Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 24:12, 1877-1886
CrossRef95
Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, Samir K Gupta, John W Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F Rooney, Judith A Aberg. (2010) A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24:11, 1781-1784
CrossRef96
Kathleen Falster, Handan Wand, Basil Donovan, Jonathan Anderson, David Nolan, Kerrie Watson, Jo Watson, Matthew G Law. (2010) Hospitalizations in a cohort of HIV patients in Australia, 1999–2007. AIDS 24:9, 1329-1339
CrossRef97
Roy J. Kim, Richard M. Rutstein. (2010) Impact of Antiretroviral Therapy on Growth, Body Composition and Metabolism in Pediatric HIV Patients. Pediatric Drugs 12:3, 187-199
CrossRef98
Ingjerd W. Manner, Morten Baekken, Olav Oektedalen, Leiv Sandvik, Ingrid Os. (2010) Effect of HIV duration on ambulatory blood pressure in HIV-infected individuals with high office blood pressure. Blood Pressure 19:3, 188-195
CrossRef99
Marion A.M. den Boer, Marit Westerterp, Jitske de Vries-van der Weij, Yanan Wang, Lihui Hu, Sonia M.S. Espirito Santo, Teake Kooistra, Peter Reiss, Johannes A. Romijn, Louis M. Havekes, Patrick C.N. Rensen. (2010) Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis 210:2, 381-387
CrossRef100
A. S. Wierzbicki, B. S. Peters. (2010) Putting protection first: vascular risk assessment in atypical populations. International Journal of Clinical Practice 64:6, 664-666
CrossRef101
Rakesh K. Mishra. (2010) Cardiac Emergencies in Patients with HIV. Emergency Medicine Clinics of North America 28:2, 273-282
CrossRef102
Giuseppe Pontrelli, Alessandra M Martino, Hyppolite K Tchidjou, Rita Citton, Nadia Mora, Lucilla Ravà, Alberto E Tozzi, Paolo Palma, Maurizio Muraca, Elisabetta Franco, Paolo Rossi, Stefania Bernardi. (2010) HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 24:8, 1145-1151
CrossRef103
Carl J. Fichtenbaum. (2010) Does Antiretroviral Therapy Increase or Decrease the Risk of Cardiovascular Disease?. Current HIV/AIDS Reports 7:2, 92-98
CrossRef104
Daniel M. Lugassy, Brenna M. Farmer, Lewis S. Nelson. (2010) Metabolic and Hepatobiliary Side Effects of Antiretroviral Therapy (ART). Emergency Medicine Clinics of North America 28:2, 409-419
CrossRef105
James J. Kohler, William Lewis. 2010. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. , 313-332.
CrossRef106
Dominic C Chow, James H Stein, Todd B Seto, Carol Mitchell, Narin Sriratanaviriyakul, Andrew Grandinetti, Mariana Gerschenson, Bruce Shiramizu, Scott Souza, Cecilia Shikuma. (2010) Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 24:7, 1019-1023
CrossRef107
Leonardo Calza, Roberto Manfredi, Gabriella Verucchi. (2010) Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 24:6, 789-802
CrossRef108
Jean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, Ploenchan Chetchotisakd, Jorge Corral, Neal David, Graeme Moyle, Marco Mancini, Lisa Percival, Rong Yang, Victoria Wirtz, Max Lataillade, Judith Absalon, Donnie McGrath. (2010) Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, 323-332
CrossRef109
Claudette S Satchell, Aoife G Cotter, Eileen F OʼConnor, Aaron J Peace, Anthony F Tedesco, Andrew Clare, John S Lambert, Gerard J Sheehan, Dermot Kenny, Patrick WG Mallon. (2010) Platelet function and HIV: a case–control study. AIDS 24:5, 649-657
CrossRef110
Jessica Foley, Mark Ettenhofer, Matthew J. Wright, Iraj Siddiqi, Melissa Choi, April D. Thames, Karen Mason, Steven Castellon, Charles H. Hinkin. (2010) Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. The Clinical Neuropsychologist 24:2, 265-285
CrossRef111
Matthew S Freiberg, Kathleen A McGinnis, Kevin Kraemer, Jeffrey H Samet, Joseph Conigliaro, R Curtis Ellison, Kendall Bryant, Lewis H Kuller, Amy C Justice. (2010) The Association Between Alcohol Consumption and Prevalent Cardiovascular Diseases Among HIV-Infected and HIV-Uninfected Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:2, 247-253
CrossRef112
Carly Skamra, Rosalind Ramsey-Goldman. (2010) Management of cardiovascular complications in systemic lupus erythematosus. International Journal of Clinical Rheumatology 5:1, 75-100
CrossRef113
Yicong Ye, Yong Zeng, Xiaomeng Li, Shuyang Zhang, Quan Fang, Ling Luo, Zhifeng Qiu, Yang Han, Taisheng Li. (2010) HIV Infection: An Independent Risk Factor of Peripheral Arterial Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:2, 276-278
CrossRef114
José Moltó, Elisabet Deig, Marta Valle, Josep Maria Llibre, Cristina Miranda, Samandhy Cedeño, Silvia Valero, Eugenia Negredo, Bonaventura Clotet. (2010) Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. Therapeutic Drug Monitoring 32:1, 93-96
CrossRef115
A.C. BECKER, K. SLIWA, S. STEWART, E. LIBHABER, A.R. ESSOP, C.A. ZAMBAKIDES, M.R. ESSOP. (2010) Acute Coronary Syndromes in Treatment-Naïve Black South Africans with Human Immunodeficiency Virus Infection. Journal of Interventional Cardiology 23:1, 70-77
CrossRef116
Patrick WG Mallon. (2010) HIV and bone mineral density. Current Opinion in Infectious Diseases 23:1, 1-8
CrossRef117
Vivek Nagaraja, Joel A. Terriquez, Hemanth Gavini, Lokesh Jha, Stephen A. Klotz. (2010) Pulmonary Embolism Mimicking Pneumonia in a HIV Patient. Case Reports in Medicine 2010, 1-3
CrossRef118
Jennifer Jao, Christina M. Wyatt. (2010) Antiretroviral Medications: Adverse Effects on the Kidney. Advances in Chronic Kidney Disease 17:1, 72-82
CrossRef119
Alison Morris, David M Guidot. (2010) Obstructive lung disease and HIV/AIDS in the HAART era. HIV Therapy 4:1, 41-54
CrossRef120
Giovanni Guaraldi, Chiara Stentarelli, Stefano Zona, Gabriella Orlando, Federica Carli, Guido Ligabue, Antonella Lattanzi, Giacomo Zaccherini, Rosario Rossi, Maria Grazia Modena, Nikolaos Alexopoulos, Frank Palella, Paolo Raggi. (2010) Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 208:1, 222-227
CrossRef121
Signe W Worm, Nina Friis-Møller, Mathias Bruyand, Antonella DʼArminio Monforte, Martin Rickenbach, Peter Reiss, Wafaa El-Sadr, Andrew Phillips, Jens Lundgren, Caroline Sabin. (2010) High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 24:3, 427-435
CrossRef122
José Ignacio Bernardino de la Serna, Francisco Xavier Zamora, María Luisa Montes, Juan García-Puig, José Ramón Arribas. (2010) Hipertensión arterial, infección por el virus de la inmunodeficiencia humana y tratamiento antirretrovírico de gran actividad. Enfermedades Infecciosas y Microbiología Clínica 28:1, 32-37
CrossRef123
Ling Luo, Lu Zhang, Meimei Tao, Zhifeng Qiu, Jing Xie, Yang Han, Ming Li, Taisheng Li. (2009) Adiponectin and Leptin Levels in Chinese Patients with HIV-Related Lipodystrophy: A 30-Month Prospective Study. AIDS Research and Human Retroviruses 25:12, 1265-1272
CrossRef124
Xinwen Wang, Dan Liao, Peter H Lin, Qizhi Yao, Changyi Chen. (2009) Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. Laboratory Investigation 89:12, 1355-1363
CrossRef125
Pamela Vergara-Rodriguez, Sonia Vibhakar, Jeff Watts. (2009) Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. Pharmacology & Therapeutics 124:3, 269-278
CrossRef126
Sanjay Bhattacharya, Husam Osman. (2009) Novel targets for anti-retroviral therapy. Journal of Infection 59:6, 377-386
CrossRef127
Eefje Jong, Susan Louw, Joost C.M. Meijers, Martijn D. de Kruif, Hugo ten Cate, Harry R. Büller, Jan Willem Mulder, Eric C.M. van Gorp. (2009) The Hemostatic Balance in HIV-Infected Patients with and without Antiretroviral Therapy: Partial Restoration with Antiretroviral Therapy. AIDS Patient Care and STDs 23:12, 1001-1007
CrossRef128
Michael S Boger, Ayumi Shintani, Leigh Anne Redhage, Valerie Mitchell, David W Haas, Jason D Morrow, Todd Hulgan. (2009) Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:4, 480-487
CrossRef129
Carlos Tornero, Carmen Mafé. (2009) Varenicline and Antiretroviral Therapy in Patients With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:5, 656
CrossRef130
Kathleen Falster, Jun Yong Choi, Basil Donovan, Chris Duncombe, Brian Mulhall, David Sowden, Jialun Zhou, Matthew G Law. (2009) AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 23:17, 2323-2336
CrossRef131
A. Maagaard, D. Kvale. (2009) Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?. Journal of Antimicrobial Chemotherapy 64:5, 901-909
CrossRef132
Elizabeth E. Lloyd-Richardson, Cassandra A. Stanton, George D. Papandonatos, William G. Shadel, Michael Stein, Karen Tashima, Timothy Flanigan, Kathleen Morrow, Charles Neighbors, Raymond Niaura. (2009) Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction 104:11, 1891-1900
CrossRef133
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, 910-928
CrossRef134
Erdembileg Anuurad, Alison Semrad, Lars Berglund. (2009) Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy–Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease. Metabolic Syndrome and Related Disorders 7:5, 401-409
CrossRef135
Lesley Wise, John Parkinson, June Raine, Alasdair Breckenridge. (2009) New approaches to drug safety: a pharmacovigilance tool kit. Nature Reviews Drug Discovery
CrossRef136
Joaquín Portilla. (2009) Factores de riesgo cardiovascular dependientes del paciente en población con infección por VIH. Enfermedades Infecciosas y Microbiología Clínica 27, 10-16
CrossRef137
Cheryl L. McDonald, Jonathan R. Kaltman. (2009) Cardiovascular Disease in Adult and Pediatric HIV/AIDS. Journal of the American College of Cardiology 54:13, 1185-1188
CrossRef138
Inés Pérez-Camacho, Ángela Camacho, Julián Torre-Cisneros, Antonio Rivero. (2009) Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral. Enfermedades Infecciosas y Microbiología Clínica 27, 24-32
CrossRef139
José Ignacio Bernardino De La Serna, José Ramón Arribas López. (2009) Controversias y futuro del abordaje de la enfermedad cardiovascular en pacientes con VIH. Enfermedades Infecciosas y Microbiología Clínica 27, 48-53
CrossRef140
Priscilla Y Hsue, Peter W Hunt, Yuaner Wu, Amanda Schnell, Jennifer E Ho, Hiroyu Hatano, Yu Xie, Jeffrey N Martin, Peter Ganz, Steven G Deeks. (2009) Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23:15, 2021-2027
CrossRef141
Fernando Lozano. (2009) Espectro de enfermedad cardiovascular en pacientes infectados por el VIH. Enfermedades Infecciosas y Microbiología Clínica 27, 3-9
CrossRef142
Peter M. Farrugia, Richard Lucariello, John T. Coppola. (2009) Human Immunodeficiency Virus and Atherosclerosis. Cardiology in Review 17:5, 211-215
CrossRef143
Sebastián Hernández, Magdalena Vidal, Enric Pedrol. (2009) Evaluación del riesgo cardiovascular e intervención en los pacientes con VIH. Enfermedades Infecciosas y Microbiología Clínica 27, 40-47
CrossRef144
Jason M. Lazar, Xi Wu, Qiuhu Shi, Abel Kagame, Mardge Cohen, Agnes Binagwaho, Louis Munyakazi, Louis Salciccioli, Di Shi, Kathryn Anastos. (2009) Arterial Wave Reflection in HIV-Infected and HIV-Uninfected Rwandan Women. AIDS Research and Human Retroviruses 25:9, 877-882
CrossRef145
Munir Pirmohamed. (2009) Clinical management of HIV-associated lipodystrophy. Current Opinion in Lipidology 20:4, 309-314
CrossRef146
C Demacq, V B Vasconcellos, A M Marcaccini, R F Gerlach, A A Machado, J E Tanus-Santos. (2009) A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The Pharmacogenomics Journal 9:4, 265-273
CrossRef147
Antonio G Pacheco, Suely H Tuboi, Silvia B May, Luiz F S Moreira, Luciana Ramadas, Estevão P Nunes, Mônica Merçon, José C Faulhaber, Lee H Harrison, Mauro Schechter. (2009) Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:5, 624-630
CrossRef148
John Lekakis, Ignatios Ikonomidis, John Palios, Sotirios Tsiodras, Emmanouil Karatzis, Garyfalia Poulakou, Loukianos Rallidis, Anastasia Antoniadou, Periklis Panagopoulos, Antonios Papadopoulos, Helen Triantafyllidi, Helen Giamarellou, Dimitrios T. Kremastinos. (2009) Association of Highly Active Antiretroviral Therapy With Increased Arterial Stiffness in Patients Infected With Human Immunodeficiency Virus. American Journal of Hypertension 22:8, 828-834
CrossRef149
Takara L Stanley, Tisha Joy, Colleen M Hadigan, James G Liebau, Hideo Makimura, Cindy Y Chen, Bijoy J Thomas, Steven B Weise, Gregory K Robbins, Steven K Grinspoon. (2009) Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 23:11, 1349-1357
CrossRef150
Rosario Rossi, Annachiara Nuzzo, Giovanni Guaraldi, Nicola Squillace, Gabriella Orlando, Roberto Esposito, Antonella Lattanzi, Maria G. Modena. (2009) Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients. Metabolism 58:7, 927-933
CrossRef151
Xiushui Ren, Marina Trilesskaya, Damon M. Kwan, Kim Nguyen, Richard E. Shaw, Peter Y. Hui. (2009) Comparison of Outcomes Using Bare Metal Versus Drug-Eluting Stents in Coronary Artery Disease Patients With and Without Human Immunodeficiency Virus Infection. The American Journal of Cardiology 104:2, 216-222
CrossRef152
Li Zhao, Derek C. Galligan, Susanna L. Lamers, Stephanie Yu, Lamia Shagrun, Marco Salemi, Michael S. McGrath. (2009) High level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS. Science in China Series C: Life Sciences 52:7, 651-656
CrossRef153
Gregory A. Hand, Jason R. Jaggers, G. William Lyerly, Wesley D. Dudgeon. (2009) Physical activity in cardiovascular disease prevention in patients with HIV/AIDS. Current Cardiovascular Risk Reports 3:4, 288-295
CrossRef154
Allison Martin, Sean Emery. (2009) Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy. Expert Review of Clinical Pharmacology 2:4, 381-390
CrossRef155
Nancy R. Reynolds. (2009) Cigarette Smoking and HIV: More Evidence for Action. AIDS Education and Prevention 21:3_supplement, 106-121
CrossRef156
Guijing Lu, Asha Thomas-Geevarghese, Erdembileg Anuurad, Subhashree Raghavan, Robert Minolfo, Bernard Ormsby, Wahida Karmally, Wafaa M. El-Sadr, Jeanine Albu, Lars Berglund. (2009) Relationship of Postprandial Nonesterified Fatty Acids, Adipokines, and Insulin Across Gender in Human Immunodeficiency Virus–Positive Patients Undergoing Highly Active Antiretroviral Therapy. Metabolic Syndrome and Related Disorders 7:3, 199-204
CrossRef157
Dj. Jevtović, G. Dragović, D. Salemović, J. Ranin, O. Djurković-Djaković. (2009) The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomedicine & Pharmacotherapy 63:5, 337-342
CrossRef158
Katherine F. Croom, Sohita Dhillon, Susan J. Keam. (2009) Atazanavir. Drugs 69:8, 1107-1140
CrossRef159
Jim Young, Tracy R. Glass, Enos Bernasconi, Martin Rickenbach, Hansjakob Furrer, Bernard Hirschel, Philip E. Tarr, Pietro Vernazza, Manuel Battegay, Heiner C. Bucher. (2009) Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. Journal of Clinical Epidemiology 62:6, 632-641
CrossRef160
Ugo Oliviero, Giovanni Bonadies, Valentina Apuzzi, Maria Foggia, Giorgio Bosso, Salvatore Nappa, Antonio Valvano, Enrico Leonardi, Guglielmo Borgia, Giuseppe Castello, Raffaele Napoli, Luigi Saccà. (2009) Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 204:2, 586-589
CrossRef161
Shadi Nahvi, Nina A. Cooperman. (2009) Review: The Need for Smoking Cessation Among HIV-Positive Smokers. AIDS Education and Prevention 21:3_supplement, 14-27
CrossRef162
Priscilla Y Hsue, Peter W Hunt, Amanda Schnell, S Craig Kalapus, Rebecca Hoh, Peter Ganz, Jeffrey N Martin, Steven G Deeks. (2009) Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23:9, 1059-1067
CrossRef163
Richard H Haubrich, Sharon A Riddler, A Gregory DiRienzo, Lauren Komarow, William G Powderly, Karin Klingman, Kevin W Garren, David L Butcher, James F Rooney, David W Haas, John W Mellors, Diane V Havlir. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:9, 1109-1118
CrossRef164
Kenneth A. Lichtenstein. (2009) Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Current HIV/AIDS Reports 6:2, 77-82
CrossRef165
Cindy H Brothers, Jaime E Hernandez, Amy G Cutrell, Lloyd Curtis, Mounir Ait-Khaled, Steve J Bowlin, Sara H Hughes, Jane M Yeo, Didier H Lapierre. (2009) Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:1, 20-28
CrossRef166
Jason V Baker, W Keith Henry, James D Neaton. (2009) The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Current Opinion in HIV and AIDS 4:3, 176-182
CrossRef167
Fátima Brañas, José Antonio Serra. (2009) Infección por el virus de la inmunodeficiencia humana en el anciano. Revista Española de Geriatría y Gerontología 44:3, 149-154
CrossRef168
Charlotte V Hobbs, Shaffiq M Essajee. (2009) Early treatment of HIV: implications for resource-limited settings. Current Opinion in HIV and AIDS1
CrossRef169
Alexandra Calmy, Angèle Gayet-Ageron, Fabrizio Montecucco, Alain Nguyen, Francois Mach, Fabienne Burger, Sasiwimol Ubolyam, Andrew Carr, Kiat Ruxungtham, Bernard Hirschel, Jintanat Ananworanich. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23:8, 929-939
CrossRef170
Sax, Paul E., Baden, Lindsey R., . (2009) When to Start Antiretroviral Therapy — Ready When You Are?. New England Journal of Medicine 360:18, 1897-1899
Full Text171
Marisa Gallego, Rosario Palacios, Daniel Salas, Ana Hidalgo, Francisco Orihuela, Juan Roldán, Mariela Grana, Julián Olalla, Alfonso del Arco, Juan de Dios Colmenero, Manuel Márquez, Jesús Santos. (2009) Prevalencia de factores de riesgo cardiovascular y de síndrome metabólico en una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana del sur de España. Estudio PREGO. Clínica e Investigación en Arteriosclerosis 21:2, 62-67
CrossRef172
, G. Carosi, P. Nasta, S. Fiore, A. Matteelli, R. Cauda, E. Ferrazzi, E. Tamburrini, V. Savasi, T. Bini, M. Ravizza, A. Bucceri, F. Vichi, R. Murri, F. Mazzotta, A. d’Arminio Monforte. (2009) Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection 37:2, 168-178
CrossRef173
(2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 373:9672, 1352-1363
CrossRef174
Juan Pedro-Botet. (2009) Infección por el VIH, síndrome metabólico y riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 21:2, 68-70
CrossRef175
Leonardo Calza, Daria Pocaterra, Michele Pavoni, Vincenzo Colangeli, Roberto Manfredi, Gabriella Verucchi, Francesco Chiodo, Marco Cantu, Milena Pariali. (2009) Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-Positive Patients Versus 51 HIV-Negative Healthy Controls. JAIDS Journal of Acquired Immune Deficiency Syndromes 50:4, 430-432
CrossRef176
Marco Floridia, Enrica Tamburrini, Gianfranco Anzidei, Cecilia Tibaldi, Giovanni Guaraldi, Brunella Guerra, Alessandra Meloni, Antonella Vimercati, Atim Molinari, Carmela Pinnetti, Serena Dalzero, Marina Ravizza. (2009) Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. AIDS Patient Care and STDs 23:3, 147-152
CrossRef177
Judith A. Aberg. (2009) Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy. Endocrinology & Metabolism Clinics of North America 38:1, 207-222
CrossRef178
Ralf Nass, Michael O Thorner. (2009) Does low-dose growth hormone therapy improve the body composition of patients infected with HIV?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 142-143
CrossRef179
Matthew S. Freiberg, David A. Leaf, Joseph L. Goulet, Matthew B. Goetz, Krisann K. Oursler, Cynthia L. Gibert, Maria C. Rodriguez-Barradas, Adeel A. Butt, Amy C. Justice. (2009) The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. Journal of General Internal Medicine 24:3, 334-340
CrossRef180
Giordano Madeddu, Giovanni Rezza, Maria Stella Mura. (2009) Trends in the European HIV/AIDS epidemic: a perspective from Italy. Expert Review of Anti-infective Therapy 7:1, 25-36
CrossRef181
Amina A. Chaudhry, Allen L. Gifford, Joseph Cofrancesco Jr., James Sosman, Gail Berkenblit, Lynn E. Sullivan. (2009) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 24:2, 276-282
CrossRef182
L. Slama, C. Le Camus, L. Serfaty, G. Pialoux, J. Capeau, S. Gharakhanian. (2009) Metabolic disorders and chronic viral disease: The case of HIV and HCV. Diabetes & Metabolism 35:1, 1-11
CrossRef183
Nirupa Patel, Neej Patel, Luis R. Espinoza. (2009) HIV Infection and Rheumatic Diseases: The Changing Spectrum of Clinical Enigma. Rheumatic Disease Clinics of North America 35:1, 139-161
CrossRef184
Filip Josephson, Jan Albert, Leo Flamholc, Magnus Gisslén, Olof Karlström, Lars Moberg, Lars Navér, Veronica Svedhem, Bo Svennerholm, Anders Sönnerborg. (2009) Treatment of HIV infection: Swedish recommendations 2009. Scandinavian Journal of Infectious Diseases 41:11-12, 788-807
CrossRef185
Délio Marques Conde, Emanuela T. Silva, Waldemar N. Amaral, Marta F. Finotti, Rui G. Ferreira, Lúcia Costa-Paiva, Aarão M. Pinto-Neto. (2009) HIV, reproductive aging, and health implications in women. Menopause 16:1, 199-213
CrossRef186
V. Balabaud, J.-L. Pourriat. (2009) Anestesia del paziente sieropositivo. EMC - Anestesia-Rianimazione 14:3, 1-17
CrossRef187
Joseph Cofrancesco, Eric Freedland, Grace McComsey. (2009) Treatment Options for HIV-Associated Central Fat Accumulation. AIDS Patient Care and STDs 23:1, 5-18
CrossRef188
Anne Maagaard, Dag Kvale. (2009) Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicity. Scandinavian Journal of Infectious Diseases 41:11-12, 808-817
CrossRef189
Sara Hughes, Robert L. Cuffe, Alfons Lieftucht, W. Garrett Nichols. (2009) Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharmaceutical Statistics 8:1, 25-37
CrossRef190
Andrew Carr, Janaki Amin. (2009) Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 23:3, 343-353
CrossRef191
Gretchen M. Ray. (2009) Antiretroviral and Statin Drug-Drug Interactions. Cardiology in Review 17:1, 44-47
CrossRef192
G. DOLAN, C. HERMANS, R. KLAMROTH, R. MADHOK, R. E. G. SCHUTGENS, U. SPENGLER. (2009) Challenges and controversies in haemophilia care in adulthood. Haemophilia 15, 20-27
CrossRef193
Carl J. Fichtenbaum. (2009) Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Current Infectious Disease Reports 11:1, 84-92
CrossRef194
Jussi Sutinen. (2009) The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients. PPAR Research 2009, 1-15
CrossRef195
Patrick W. G. Mallon, Rebecca Sedwell, Gary Rogers, David Nolan, Patrick Unemori, Jennifer Hoy, Katherine Samaras, Anthony Kelleher, Sean Emery, David A. Cooper, Andrew Carr, . (2008) Effect of Rosiglitazone on Peroxisome Proliferator‐Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug–Induced Mitochondrial Dysfunction. The Journal of Infectious Diseases 198:12, 1794-1803
CrossRef196
Phyllis C Tien, Michael F Schneider, Stephen R Cole, Alexandra M Levine, Mardge Cohen, Jack DeHovitz, Mary Young, Jessica E Justman. (2008) Antiretroviral Therapy Exposure and Insulin Resistance in the Womenʼs Interagency HIV Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:4, 369-376
CrossRef197
Daniel J Skiest, Amy Krambrink, Zhaohui Su, Kevin R Robertson, David M Margolis. (2008) Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:4, 377-383
CrossRef198
Kelly A Gebo. (2008) Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 4:6, 615-627
CrossRef199
Allison C Ross, Rachel Armentrout, Mary Ann OʼRiordan, Norma Storer, Nesrine Rizk, Danielle Harrill, Dalia El Bejjani, Grace A McComsey. (2008) Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:5, 499-506
CrossRef200
Antonio Antela López. (2008) Utilidad de atazanavir en poblaciones especiales. Enfermedades Infecciosas y Microbiología Clínica 26, 49-54
CrossRef201
Esteban Martínez Chamorro. (2008) Perfil lipídico de atazanavir. Enfermedades Infecciosas y Microbiología Clínica 26, 34-40
CrossRef202
Andrew N Phillips, James Neaton, Jens D Lundgren. (2008) The role of HIV in serious diseases other than AIDS. AIDS 22:18, 2409-2418
CrossRef203
Anne-Mette Lebech, Ulrik Sloth Kristoffersen, Niels Wiinberg, Kristian Kofoed, Ove Andersen, Birger Hesse, Claus Leth Petersen, Jan Gerstoft, Andreas Kjær. (2008) Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. European Journal of Nuclear Medicine and Molecular Imaging 35:11, 2049-2058
CrossRef204
Morten Baekken, Ingrid Os, Leiv Sandvik, Olav Oektedalen. (2008) Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. Journal of Hypertension 26:11, 2126-2133
CrossRef205
Julie Ann Smith. (2008) HIV and AIDS in the Adolescent and Adult: An Update for the Oral and Maxillofacial Surgeon. Oral and Maxillofacial Surgery Clinics of North America 20:4, 535-565
CrossRef206
David A. Wohl, David Waters, Ross J. Simpson, Susan Richard, Amanda Schnell, Sonia Napravnik, Jessica Keys, J. Joseph Eron, Priscilla Hsue. (2008) Ezetimibe Alone Reduces Low‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy. Clinical Infectious Diseases 47:8, 1105-1108
CrossRef207
V.J. Moreno Cuerda, R. Rubio García, C. Barros Aguado, M. Morales Conejo. (2008) Nuevos fármacos antirretrovirales: inhibidores del CCR5 y de la integrasa. Revista Clínica Española 208:9, 463-466
CrossRef208
(2008) HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22:16, 2143-2153
CrossRef209
Leonardo Calza, Alessandra Cascavilla, Daria Pocaterra, Roberto Manfredi, Vincenzo Colangeli, Francesco Chiodo. (2008) Clinical, Epidemiological, and Laboratory Characteristics of Myocardial Infarction in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy. Infectious Diseases in Clinical Practice 16:5, 288-293
CrossRef210
Donald P Kotler. (2008) HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:Supplement 2, S79-S85
CrossRef211
Arvind Venkat, David M. Piontkowsky, Robert R. Cooney, Adarsh K. Srivastava, Gregory A. Suares, Cory P. Heidelberger. (2008) Care of the HIV-Positive Patient in the Emergency Department in the Era of Highly Active Antiretroviral Therapy. Annals of Emergency Medicine 52:3, 274-285
CrossRef212
Franck Boccara. (2008) Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22:Suppl 3, S19-S26
CrossRef213
(2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22:14, F17-F24
CrossRef214
Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel, Ralph Turner, Steven Grinspoon. (2008) Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22:14, 1719-1728
CrossRef215
Robert C Kaplan, Lawrence A Kingsley, Stephen J Gange, Lorie Benning, Lisa P Jacobson, Jason Lazar, Kathryn Anastos, Phyllis C Tien, A Richey Sharrett, Howard N Hodis. (2008) Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22:13, 1615-1624
CrossRef216
Carlo Torti, Ian Frank. (2008) A king in the CASTLE? Optimum initial HIV protease inhibitor. The Lancet 372:9639, 604-606
CrossRef217
Jean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, Ploenchan Chetchotisakd, Jorge Corral, Neal David, Graeme Moyle, Marco Mancini, Lisa Percival, Rong Yang, Alexandra Thiry, Donnie McGrath. (2008) Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. The Lancet 372:9639, 646-655
CrossRef218
Elena Seoane, Salvador Resino, Dariela Micheloud, Ana Moreno, Juan C. L Bernaldo de Quiros, Raquel Lorente, Rafael Rubio, Juan Gonzalez, Federico Pulido, José R Arribas, Santiago Moreno, Má Muñoz-Fernández. (2008) Lipid and Apoprotein Profile in HIV-1-Infected Patients After CD4-Guided Treatment Interruption. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:4, 455-459
CrossRef219
Koustubh Ranade, William J Geese, Mustafa Noor, Oliver Flint, Pablo Tebas, Kathleen Mulligan, William Powderly, Steven K Grinspoon, Michael P Dube. (2008) Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 22:13, 1561-1568
CrossRef220
Magdalena E Sobieszczyk, Donald R Hoover, Kathryn Anastos, Kathleen Mulligan, Tianren Tan, Qiuhu Shi, Wei Gao, Charles Hyman, Mardge H Cohen, Stephen R Cole, Michael W Plankey, Alexandra M Levine, Jessica Justman. (2008) Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected and HIV-Uninfected Women in the Womenʼs Interagency HIV Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:3, 272-280
CrossRef221
Sharon A Riddler, Xiuhong Li, James Otvos, Wendy Post, Frank Palella, Lawrence Kingsley, Barbara Visscher, Lisa P Jacobson, A R Sharrett. (2008) Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:3, 281-288
CrossRef222
S. Badiou, R. Thiebaut, V. Aurillac-Lavignolle, F. Dabis, F. Laporte, J.P. Cristol, P. Mercie. (2008) Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. Journal of Infection 57:1, 47-54
CrossRef223
Blai Coll, Anna Cabre, Carlos Alonso-Villaverde, Iolanda Lazaro, Gerard Aragonés, Sandra Parra, Josefa Girona, Lluis Masana. (2008) The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 199:1, 147-153
CrossRef224
Félix Gutiérrez, Enrique Bernal, Sergio Padilla, Ildefonso Hernández, Mar Masiá. (2008) Relationship between ankle–brachial index and carotid intima-media thickness in HIV-infected patients. AIDS 22:11, 1369-1371
CrossRef225
Marianne Harris. (2008) Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Drug Safety 7:4, 389-400
CrossRef226
Giuseppe Vittorio L. De Socio, Giustino Parruti, Tiziana Quirino, Elena Ricci, Giuseppe Schillaci, Beatrice Adriani, Patrizia Marconi, Marzia Franzetti, Canio Martinelli, Francesca Vichi, Giovanni Penco, Claudio Sfara, Giordano Madeddu, Paolo Bonfanti. (2008) Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. Journal of Infection 57:1, 33-40
CrossRef227
Laurence Fardet, Adrien Kettaneh, Kiet-Phong Tiev, Bénédicte Fabre, Cécile Tolédano, Jean Cabane, Antoine Flahault. (2008) Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. European Journal of Internal Medicine 19:5, 340-344
CrossRef228
Kate Buchacz, Rose K Baker, Anne C Moorman, James T Richardson, Kathleen C Wood, Scott D Holmberg, John T Brooks. (2008) Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS 22:11, 1345-1354
CrossRef229
Enrique Bernal, Mar Masiá, Sergio Padilla, Félix Gutiérrez. (2008) High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition. AIDS Patient Care and STDs 22:7, 569-575
CrossRef230
J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, M. Pirmohamed. (2008) HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. Journal of Antimicrobial Chemotherapy 62:4, 648-660
CrossRef231
M. Baekken, I. Os, L. Sandvik, O. Oektedalen. (2008) Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrology Dialysis Transplantation 23:10, 3130-3137
CrossRef232
Thi Tuyet Nhung Vo, Bruno Ledergerber, Olivia Keiser, Bernard Hirschel, Hansjakob Furrer, Manuel Battegay, Matthias Cavassini, Enos Bernasconi, Pietro Vernazza, Rainer Weber, . (2008) Durability and Outcome of Initial Antiretroviral Treatments Received during 2000–2005 by Patients in the Swiss HIV Cohort Study. The Journal of Infectious Diseases 197:12, 1685-1694
CrossRef233
Jason S Reingold, Christine Wanke, Donald P Kotler, Cora E Lewis, Russell Tracy, Steven Heymsfield, Phyllis C Tien, Peter Bacchetti, Rebecca Scherzer, Carl Grunfeld, Michael G Shlipak. (2008) Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels. JAIDS Journal of Acquired Immune Deficiency Syndromes 48:2, 142-148
CrossRef234
Graeme Moyle, Jose Gatell, Carlo-Federico Perno, Winai Ratanasuwan, Mauro Schechter, Christos Tsoukas. (2008) Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection. AIDS Patient Care and STDs 22:6, 459-471
CrossRef235
R. A. Bradbury, K. Samaras. (2008) Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost?. Diabetes, Obesity and Metabolism 10:6, 441-450
CrossRef236
Carlos Tornero Estébanez, Alicia Santamaría Martín, Eva Gil Tomás, Consuelo Lapuebla Ferri. (2008) Índices de riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento antirretroviral efectivo. Medicina Clínica 130:20, 797
CrossRef237
Caroline A Sabin, Signe W Worm. (2008) Conventional cardiovascular risk factors in HIV infection: how conventional are they?. Current Opinion in HIV and AIDS 3:3, 214-219
CrossRef238
David Burger, Erik Stroes, Peter Reiss. (2008) Drug interactions between statins and antiretroviral agents. Current Opinion in HIV and AIDS 3:3, 247-251
CrossRef239
John R. Koethe, Richard D. Moore, Krystn R. Wagner. (2008) Physician Specialization and Women's Primary Care Services in an Urban HIV Clinic. AIDS Patient Care and STDs 22:5, 373-380
CrossRef240
Andrew Carr. (2008) Pathogenesis of cardiovascular disease in HIV infection. Current Opinion in HIV and AIDS 3:3, 234-239
CrossRef241
Esteban Martínez, Pere Leyes, Emilio Ros. (2008) Effectiveness of lipid-lowering therapy in HIV patients. Current Opinion in HIV and AIDS 3:3, 240-246
CrossRef242
Shilpa Patel, Elisa Weiss, Rosy Chhabra, Laura Ryniker, Roberto Adsuar, Jason Carness, Wendy Kahalas, Carol DeLaMarter, Ira S. Feldman, Judy P. Delorenzo, Ellen Tanner, Bruce Rapkin. (2008) The Events in Care Screening Questionnaire (ECSQ): A New Tool to Identify Needs and Concerns of People with HIV/AIDS. AIDS Patient Care and STDs 22:5, 381-393
CrossRef243
M. Guiguet, M. Mary-Krause, B. Ename, D. Costagliola, S. Grabar. (2008) Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). Pharmacoepidemiology and Drug Safety 17:5, 468-474
CrossRef244
Janet Lo, Steven Grinspoon. (2008) Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk?. Current Opinion in HIV and AIDS 3:3, 207-213
CrossRef245
Erdembileg Anuurad, Asha Thomas-Geevarghese, Sridevi Devaraj, Jeanine Albu, Robert Minolfo, Wafaa M. El-Sadr, Guijing Lu, Wahida Karmally, Lars Berglund. (2008) Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis 198:1, 192-197
CrossRef246
Nina Friis-Møller, Marek Smieja, Daniel Klein. (2008) Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. Current Opinion in HIV and AIDS 3:3, 220-225
CrossRef247
M. del Mar Gutiérrez Maciá, M. Gracia Mateo García, Francesc Vidal Marsal, Pere Domingo Pedrol. (2008) Toxicogenética del tratamiento antirretroviral (I): lipodistrofia, alteraciones metabólicas y arteriosclerosis. Enfermedades Infecciosas y Microbiología Clínica 26, 18-23
CrossRef248
(2008) Inferior Clinical Outcome of the CD4 + Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4 + Cell Counts and HIV RNA Levels during Follow‐up. The Journal of Infectious Diseases 197:8, 1145-1155
CrossRef249
(2008) Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. The Journal of Infectious Diseases 197:8, 1133-1144
CrossRef250
L. Nelson, K.J. Stewart. (2008) HIV and the surgeon. Journal of Plastic, Reconstructive & Aesthetic Surgery 61:4, 355-358
CrossRef251
John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, Robert A Zackin, Stéphannie Charles, Evelyn Hogg, Edward P Acosta, Elizabeth Connick, David Wohl, E Milu Kojic, Constance A Benson, Judith A Aberg. (2008) Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:4, 459-466
CrossRef252
MT Bennett, KW Johns, GP Bondy. (2008) Current and future treatments of HIV-associated dyslipidemia. Future Lipidology 3:2, 175-188
CrossRef253
Jason V Baker, Grace Peng, Joshua Rapkin, Donald I Abrams, Michael J Silverberg, Rodger D MacArthur, Winston P Cavert, W Keith Henry, James D Neaton. (2008) CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22:7, 841-848
CrossRef254
Jennifer J Kiser, John G Gerber, Julie A Predhomme, Pamela Wolfe, Devon M Flynn, Dorie W Hoody. (2008) Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:5, 570-578
CrossRef255
(2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. The Lancet 371:9622, 1417-1426
CrossRef256
Paola Nasta, Francesca Gatti, Massimo Puoti, Giuliana Cologni, Viviana Bergamaschi, Federica Borghi, Alessandro Matti, Antonella Ricci, Giampiero Carosi. (2008) Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 22:7, 857-861
CrossRef257
M. M. Melendez, M. A. McNurlan, D. C. Mynarcik, S. Khan, M. C. Gelato. (2008) Endothelial Adhesion Molecules Are Associated with Inflammation in Subjects with HIV Disease. Clinical Infectious Diseases 46:5, 775-780
CrossRef258
T. Neumann. (2008) HIV, AIDS und kardiovaskuläres Risiko. Der Internist 49:4, 429-435
CrossRef259
Sean T Nguyen, Susan A Eaton, Amy M Bain, Anita P Rahman, Kenna D Payne, Roger Bedimo, Jon D Herrington, Darego O Maclayton, Maria C Rodriguez-Barradas, Anthony J Busti. (2008) Lipid-Lowering Efficacy and Safety After Switching to Atazanavir-Ritonavir–Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus. Pharmacotherapy 28:3, 323-330
CrossRef260
D. Periard, M. Cavassini, P. Taffe, M. Chevalley, L. Senn, C. Chapuis-Taillard, S. de Valliere, D. Hayoz, P. E. Tarr, . (2008) High Prevalence of Peripheral Arterial Disease in HIV-Infected Persons. Clinical Infectious Diseases 46:5, 761-767
CrossRef261
Kate Buchacz, Paul J Weidle, David Moore, Willy Were, Jonathan Mermin, Robert Downing, Aminah Kigozi, Craig B Borkowf, Vincent Ndazima, John T Brooks. (2008) Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:3, 304-311
CrossRef262
Zachariah Dorey-Stein, Valerianna K. Amorosa, Jay R. Kostman, Vincent Lo Re, Richard P. Shannon. (2008) Severe Weight Gain, Lipodystrophy, Dyslipidemia, and Obstructive Sleep Apnea in a Human Immunodeficiency Virus-Infected Patient Following Highly Active Antiretroviral Therapy. Journal of the CardioMetabolic Syndrome 3:2, 111-114
CrossRef263
Dominic N. Reeds. (2008) Metabolic Syndrome Risks of Cardiovascular Disease: Differences Between HIV-Positive and HIV-Negative?. Journal of the CardioMetabolic Syndrome 3:2, 79-82
CrossRef264
James D Neaton, Birgit Grund. (2008) Earlier initiation of antiretroviral therapy in treatment-na??ve patients: implications of results of treatment interruption trials. Current Opinion in HIV and AIDS 3:2, 112-117
CrossRef265
Valérie Journot, Sophie Tabuteau, Fidéline Collin, Jean-Michel Molina, Geneviève Chene, Corinne Rancinan. (2008) About the necessity to manage events coded with MedDRA prior to statistical analysis: Proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE. Contemporary Clinical Trials 29:2, 95-101
CrossRef266
Tanvi S. Sharma, Sarah Messiah, Stacy Fisher, Tracie L. Miller, Steven E. Lipshultz. (2008) Accelerated Cardiovascular Disease and Myocardial Infarction Risk in Patients With the Human Immunodeficiency Virus. Journal of the CardioMetabolic Syndrome 3:2, 93-97
CrossRef267
M Colafigli, S Di Giambenedetto, L Bracciale, E Tamburrini, R Cauda, A De Luca. (2008) Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Medicine 9:3, 172-179
CrossRef268
Eugene Mutimura, Nigel J. Crowther, Aimee Stewart, W. Todd Cade. (2008) The Human Immunodeficiency Virus and the Cardiometabolic Syndrome in the Developing World: An African Perspective. Journal of the CardioMetabolic Syndrome 3:2, 106-110
CrossRef269
S. Lai, E. K. Fishman, H. Lai, R. Moore, J. Cofrancesco, H. Pannu, W. Tong, J. Du, J. Bartlett. (2008) Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. Clinical Infectious Diseases 46:4, 600-610
CrossRef270
D. R (Niel) Malan, Edrich Krantz, Neal David, Victoria Wirtz, Janet Hammond, Donnie McGrath. (2008) Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:2, 161-167
CrossRef271
Edward Stenehjem, Judith C Shlay. (2008) Sex-specific differences in treatment outcomes for patients with HIV and AIDS. Expert Review of Pharmacoeconomics & Outcomes Research 8:1, 51-63
CrossRef272
WT Cade, DN Reeds, S Lassa-Claxton, VG Davila-Roman, AD Waggoner, WG Powderly, KE Yarasheski. (2008) Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease?. HIV Medicine 9:2, 96-100
CrossRef273
M.W. Lorenz, C. Stephan, A. Harmjanz, S. Staszewski, A. Buehler, M. Bickel, S. von Kegler, D. Ruhkamp, H. Steinmetz, M. Sitzer. (2008) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196:2, 720-726
CrossRef274
E. T. Golub, L. Benning, A. Sharma, M. Gandhi, M. H. Cohen, M. Young, S. J. Gange. (2008) Patterns, Predictors, and Consequences of Initial Regimen Type among HIV-Infected Women Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 46:2, 305-312
CrossRef275
Vivian Pao, Grace A. Lee, Carl Grunfeld. (2008) HIV therapy, metabolic syndrome, and cardiovascular risk. Current Atherosclerosis Reports 10:1, 61-70
CrossRef276
David Nolan, Simon Mallal, Peter Reiss. 2008. Complications Resulting from Antiretroviral Therapy for HIV Infection. , 181-191.
CrossRef277
Enrique Bernal, Mar Masiá, Sergio Padilla, Ildefonso Hernández, Félix Gutiérrez. (2008) Low Prevalence of Peripheral Arterial Disease in HIV-Infected Patients With Multiple Cardiovascular Risk Factors. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, 126-127
CrossRef278
Caroline A Sabin. (2008) Cardiovascular risk and choice of HIV drug regimen. Future HIV Therapy 2:1, 83-92
CrossRef279
Georg MN Behrens. (2008) Treatment options for lipodystrophy in HIV-positive patients. Expert Opinion on Pharmacotherapy 9:1, 39-52
CrossRef280
Falutz, Julian, Allas, Soraya, Blot, Koenraad, Potvin, Diane, Kotler, Donald, Somero, Michael, Berger, Daniel, Brown, Stephen, Richmond, Gary, Fessel, Jeffrey, Turner, Ralph, Grinspoon, Steven, . (2007) Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine 357:23, 2359-2370
Full Text281
Blackman, Marc R., . (2007) Manipulation of the Growth Hormone Axis in Patients with HIV Infection. New England Journal of Medicine 357:23, 2397-2399
Full Text282
Richard A. Murphy, Henry Sunpath, Daniel R. Kuritzkes, Francois Venter, Rajesh T. Gandhi. (2007) Antiretroviral Therapy–Associated Toxicities in the Resource‐Poor World: The Challenge of a Limited Formulary. The Journal of Infectious Diseases 196:s3, S449-S456
CrossRef283
Lisa M. Chastain, Amy M. Bain, Krystal L. Edwards, Roger Bedimo, Anthony J. Busti. (2007) A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. Journal of Clinical Lipidology 1:6, 634-639
CrossRef284
Jisun Oh, Robert A Hegele. (2007) HIV-associated dyslipidaemia: pathogenesis and treatment. The Lancet Infectious Diseases 7:12, 787-796
CrossRef285
Huiping Zhou, Sirikalaya Jarujaron, Emily C. Gurley, Li Chen, Hong Ding, Elaine Studer, William M. Pandak, Wenhui Hu, Tongtong Zou, Jian-Ying Wang, Phillip B. Hylemon. (2007) HIV protease inhibitors increase TNF-α and IL-6 expression in macrophages: Involvement of the RNA-binding protein HuR. Atherosclerosis 195:1, e134-e143
CrossRef286
Handan Wand, Alexandra Calmy, Dianne L Carey, Katherine Samaras, Andrew Carr, Matthew G Law, David A Cooper, Sean Emery. (2007) Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21:18, 2445-2453
CrossRef287
Blai Coll Crespo, Lluís Masana Marín. (2007) Riesgo cardiovascular en pacientes infectados por el virus de la inmunodeficiencia humana: ¿son suficientes las tablas de riesgo?. Medicina Clínica 129:14, 532-533
CrossRef288
Andres Catzin-Kuhlmann, Arturo Orea-Tejeda, Lilia Castillo-Martínez, Eloisa Colín-Ramírez, Daniel Asz, Víctor H. Aguirre, Luis E. Herrera, Victoria Valles, Carlos A. Aguilar-Salinas, Juan Sierra, Juan J. Calva. (2007) Human immunodeficiency virus-infected subjects have no altered myocardial perfusion. International Journal of Cardiology 122:1, 90-92
CrossRef289
Justyna D. Kowalska, Amanda Mocroft, Anders Blaxhult, Robert Colebunders, Jan van Lunzen, Daria Podlekareva, Ann-Brit Eg Hansen, Ladislav Machala, Israel Yust, Thomas Benfield. (2007) Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection. AIDS Research and Human Retroviruses 23:10, 1183-1188
CrossRef290
Mireia Arnedo, Patrick Taffé, Roland Sahli, Hansjakob Furrer, Bernard Hirschel, Luigia Elzi, Rainer Weber, Pietro Vernazza, Enos Bernasconi, Roger Darioli, Sven Bergmann, Jacques S. Beckmann, Amalio Telenti, Philip E. Tarr. (2007) Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and Genomics 17:9, 755-764
CrossRef291
Stefan Esser, Doris Helbig, Uwe Hillen, Joachim Dissemond, Stephan Grabbe. (2007) Side effects of HIV therapy. JDDG 5:9, 745-754
CrossRef292
Alessandro Soria, Adriano Lazzarin. (2007) Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:Suppl 1, S19-S30
CrossRef293
L Normén, B Yip, J Montaner, M Harris, J Frohlich, G Bondy, RS Hogg. (2007) Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Medicine 8:6, 346-356
CrossRef294
Julian Falutz. (2007) Therapy Insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nature Clinical Practice Endocrinology & Metabolism 3:9, 651-661
CrossRef295
T. I. de Silva, F. A. Post, M. D. Griffin, D. H. Dockrell. (2007) HIV-1 Infection and the Kidney: An Evolving Challenge in HIV Medicine. Mayo Clinic Proceedings 82:9, 1103-1116
CrossRef296
Phyllis C Tien, Michael F Schneider, Stephen R Cole, Alexandra M Levine, Mardge Cohen, Jack DeHovitz, Mary Young, Jessica E Justman. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women??s Interagency HIV Study. AIDS 21:13, 1739-1745
CrossRef297
María del Mar Gutierrez, Gracia Mateo, Pere Domingo. (2007) Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion on Pharmacotherapy 8:12, 1871-1884
CrossRef298
Christopher McCoy. (2007) Darunavir: A Nonpeptidic Antiretroviral Protease Inhibitor. Clinical Therapeutics 29:8, 1559-1576
CrossRef299
Vera P. Luther, Aimee M. Wilkin. (2007) HIV Infection in Older Adults. Clinics in Geriatric Medicine 23:3, 567-583
CrossRef300
A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fatkenheuer, JD Lundgren. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. The Lancet 370:9585, 407-413
CrossRef301
J.-J. Parienti, V. Massari, D. Rey, P. Poubeau, R. Verdon, . (2007) Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study. Clinical Infectious Diseases 45:2, 263-266
CrossRef302
SA Riddler, X Li, H Chu, LA Kingsley, A Dobs, R Evans, F Palella, B Visscher, JS Chmiel, AR Sharrett. (2007) Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Medicine 8:5, 280-287
CrossRef303
Kelley L. Clem, James R. Borchers. (2007) HIV and the Athlete. Clinics in Sports Medicine 26:3, 413-424
CrossRef304
Antoine Benard, Fabrice Bonnet, Jean-François Tessier, Helene Fossoux, Michel Dupon, Patrick Mercie, Jean-Marie Ragnaud, Jean-François Viallard, François Dabis, Genevieve Chene. (2007) Tobacco Addiction and HIV Infection: Toward the Implementation of Cessation Programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care and STDs 21:7, 458-468
CrossRef305
Michelle Floris-Moore, Andrea A. Howard, Yungtai Lo, Ellie E. Schoenbaum, Julia H. Arnsten, Robert S. Klein. (2007) Hepatitis C Infection Is Associated with Lower Lipids and High-Sensitivity C-Reactive Protein in HIV-Infected Men. AIDS Patient Care and STDs 21:7, 479-491
CrossRef306
Steen B. Haugaard, Ove Andersen, Ian Halsall, Johan Iversen, Charles Nicholas Hales, Stein Madsbad. (2007) Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metabolism 56:7, 939-946
CrossRef307
Alessandra Viganò, Vania Giacomet, Giulia Pattarino, Silvia Fasan, Gianvincenzo Zuccotti, Paolo Brambilla. (2007) Metabolic complications of HIV infection and its therapy in children. Future HIV Therapy 1:2, 181-190
CrossRef308
Emma Hammond, David Nolan. (2007) Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Current Opinion in HIV and AIDS 2:4, 274-281
CrossRef309
Patrick WG Mallon. (2007) Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Current Opinion in HIV and AIDS 2:4, 282-292
CrossRef310
B. Ledergerber, H. Furrer, M. Rickenbach, R. Lehmann, L. Elzi, B. Hirschel, M. Cavassini, E. Bernasconi, P. Schmid, M. Egger, R. Weber, . (2007) Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. Clinical Infectious Diseases 45:1, 111-119
CrossRef311
Sander I van Leuven, Raaj R Sankatsing, Joost N Vermeulen, John JP Kastelein, Peter Reiss, Erik SG Stroes. (2007) Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Current Opinion in HIV and AIDS 2:4, 324-331
CrossRef312
Tisha Joy, Hester M Keogh, Colleen Hadigan, Hang Lee, Sara E Dolan, Kathleen Fitch, James Liebau, Janet Lo, Stine Johnsen, Jane Hubbard, Ellen J Anderson, Steven Grinspoon. (2007) Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 21:12, 1591-1600
CrossRef313
N. Obel, H. F. Thomsen, G. Kronborg, C. S. Larsen, P. R. Hildebrandt, H. T. Sorensen, J. Gerstoft. (2007) Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study. Clinical Infectious Diseases 44:12, 1625-1631
CrossRef314
Susan L. Rosenkranz, Kevin E. Yarasheski, Michael F. Para, Richard C. Reichman, Gene D. Morse. (2007) Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metabolic Syndrome and Related Disorders 5:2, 163-173
CrossRef315
Yohan P. Samarasinghe. (2007) HIV and diabetes. Primary Care Diabetes 1:2, 99-101
CrossRef316
Graeme Moyle. (2007) Metabolic Issues Associated With Protease Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 1, S19-S26
CrossRef317
Sharon Walmsley. (2007) Protease Inhibitor-Based Regimens for HIV Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 1, S5-S13
CrossRef318
Luuk Gras, Anouk M Kesselring, James T Griffin, Ard I van Sighem, Christophe Fraser, Azra C Ghani, Frank Miedema, Peter Reiss, Joep M A Lange, Frank de Wolf. (2007) CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:2, 183-192
CrossRef319
Bryan Lau, Stephen J. Gange, Richard D. Moore. (2007) Interval and Clinical Cohort Studies: Epidemiological Issues. AIDS Research and Human Retroviruses 23:6, 769-776
CrossRef320
Lynda Anne Szczech, Carl Grunfeld, Rebecca Scherzer, Jesse A Canchola, Charles van der Horst, Stephen Sidney, David Wohl, Michael G Shlipak. (2007) Microalbuminuria in HIV infection. AIDS 21:8, 1003-1009
CrossRef321
Claudia Stöllberger, Christine Armbruster, Bernd Gmeinhart, Josef Finsterer. (2007) Thrombosis of a drug-eluting stent after almost 2 years in an HIV-infected patient. AIDS 21:8, 1064-1066
CrossRef322
Judith S Currier, Michelle A Kendall, W Keith Henry, Beverly Alston-Smith, Francesca J Torriani, Pablo Tebas, Yanjie Li, Howard N Hodis. (2007) Progression of carotid artery intima–media thickening in HIV-infected and uninfected adults. AIDS 21:9, 1137-1145
CrossRef323
Indira Brar, Jonathan Shuter, Avis Thomas, Eric Daniels, Judith Absalon. (2007) A Comparison of Factors Associated With Prevalent Diabetes Mellitus Among HIV-Infected Antiretroviral-Naive Individuals Versus Individuals in the National Health and Nutritional Examination Survey Cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:1, 66-71
CrossRef324
Anne-Mette Lebech, Niels Wiinberg, Ulrik Sloth Kristoffersen, Birger Hesse, Claus Leth Petersen, Jan Gerstoft, Andreas Kjær. (2007) Carotid intima?media thickness in HIV patients treated with antiretroviral therapy. Clinical Physiology and Functional Imaging 27:3, 173-179
CrossRef325
The DAD Study Group. (2007) Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine 356:17, 1723-1735
Full Text326
Hong Mu, Hong Chai, Peter H. Lin, Qizhi Yao, Changyi Chen. (2007) Current Update on HIV-associated Vascular Disease and Endothelial Dysfunction. World Journal of Surgery 31:4, 632-643
CrossRef327
Line D Rasmussen, Jan Gerstoft, Gitte Kronborg, Carsten S Larsen, Gitte Pedersen, Niels Obel. (2007) Mortality after myocardial infarction in HIV-infected patients who have initiated HAART. AIDS 21:7, 873-875
CrossRef328
Evy Micieli, Francesco Dentali, Massimo Giola, Paolo Grossi, Achille Venco, Walter Ageno. (2007) Venous and arterial thrombosis in patients with HIV infection. Blood Coagulation & Fibrinolysis 18:3, 259-263
CrossRef329
J. A. C. Sterne, M. May, H. C. Bucher, B. Ledergerber, H. Furrer, M. Cavassini, E. Bernasconi, B. Hirschel, M. Egger, . (2007) HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Journal of Internal Medicine 261:3, 255-267
CrossRef330
K. Mondy, E. T. Overton, J. Grubb, S. Tong, W. Seyfried, W. Powderly, K. Yarasheski. (2007) Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population. Clinical Infectious Diseases 44:5, 726-734
CrossRef331
Daniel E. Cohen, Kenneth H. Mayer. (2007) Primary Care Issues for HIV-Infected Patients. Infectious Disease Clinics of North America 21:1, 49-70
CrossRef332
Pierre De Truchis, Myriam Kirstetter, Antoine Perier, Claire Meunier, David Zucman, Gilles Force, Jacques Doll, Christine Katlama, Willy Rozenbaum, H??l??ne Masson, Jean Gardette, Jean-Claude Melchior. (2007) Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:3, 278-285
CrossRef333
C Holkmann Olsen, A Mocroft, O Kirk, S Vella, A Blaxhult, N Clumeck, M Fisher, C Katlama, AN Phillips, JD Lundgren, . (2007) Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine 8:2, 96-104
CrossRef334
C. Y. Jones. (2007) Metabolic Syndrome in HIV-Infected Patients: No Different than the General Population?. Clinical Infectious Diseases 44:5, 735-738
CrossRef335
Wei Zou, Lars Berglund. (2007) HIV and Highly Active Antiretroviral Therapy: Dyslipidemia, Metabolic Aberrations, and Cardiovascular Risk. Preventive Cardiology 10:2, 96-103
CrossRef336
Kristin Mondy, Pablo Tebas. (2007) Cardiovascular Risks of Antiretroviral Therapies. Annual Review of Medicine 58:1, 141-155
CrossRef337
David M. Brett-Major, Anuradha Ganesan. (2007) Dyslipidemia Management in Patients With Human Immunodeficiency Virus. Infectious Diseases in Clinical Practice 15:1, 7-16
CrossRef338
Ian J. Woolley, Xiuhong Li, Lisa P. Jacobson, Frank J. Palella, Lars Ostergaard. (2007) Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study. Sexual Health 4:2, 111
CrossRef339
Matthew S Freiberg, Debbie M Cheng, Kevin L Kraemer, Richard Saitz, Lewis H Kuller, Jeffrey H Samet. (2007) The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 21:2, 193-197
CrossRef340
Esteban Martínez, Juan C López Bernaldo de Quirós, Celia Miralles, Daniel Podzamczer. (2007) Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART. AIDS 21:3, 384-386
CrossRef341
J. J. Feiner, M. A. McNurlan, R. E. Ferris, D. C. Mynarcik, M. C. Gelato. (2006) Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study. Diabetes, Obesity and Metabolism 0:0, 061214081108006-???
CrossRef342
Alexandra Mangili, Christine A Wanke. (2006) Dyslipidemia in HIV infection. Future Lipidology 1:6, 719-728
CrossRef343
C. Jericó, H. Knobel, M.L. Sorli, M. Montero, A. Guelar, J. Pedro-Botet. (2006) Prevalencia de factores de riesgo cardiovascular en pacientes con infección por el VIH. Revista Clínica Española 206:11, 556-559
CrossRef344
Mar Masiá-Canuto, Enrique Bernal-Morell, Félix Gutiérrez-Rodero. (2006) Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral. Enfermedades Infecciosas y Microbiología Clínica 24:10, 637-648
CrossRef345
A. Mangili, J. Gerrior, A. M. Tang, D. H. O'Leary, J. K. Polak, E. J. Schaefer, S. L. Gorbach, C. A. Wanke. (2006) Risk of Cardiovascular Disease in a Cohort of HIV-Infected Adults: A Study Using Carotid Intima-Media Thickness and Coronary Artery Calcium Score. Clinical Infectious Diseases 43:11, 1482-1489
CrossRef346
Currier, Judith S., Baden, Lindsey R., . (2006) Getting Smarter — The Toxicity of Undertreated HIV Infection. New England Journal of Medicine 355:22, 2359-2361
Full Text347
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. (2006) CD4+ Count–Guided Interruption of Antiretroviral Treatment. New England Journal of Medicine 355:22, 2283-2296
Full Text348
Luminita Ene, Tessa Goetghebuer, Marc Hainaut, Alexandra Peltier, Véronique Toppet, Jack Levy. (2006) Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. European Journal of Pediatrics 166:1, 13-21
CrossRef349
Matthew G Law. (2006) Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study. Current Opinion in HIV and AIDS 1:6, 482-487
CrossRef350
Eugenia Negredo, José Moltó, Jordi Puig, Denise Cinquegrana, Anna Bonjoch, Núria Pérez-Álvarez, Raquel López-Blázquez, Asunción Blanco, Bonaventura Clotet, Celestino Rey-Joly. (2006) Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20:17, 2159-2164
CrossRef351
Priscilla Y Hsue, Peter W Hunt, Elizabeth Sinclair, Barry Bredt, Arlana Franklin, Maudi Killian, Rebecca Hoh, Jeffrey N Martin, Joseph M McCune, David D Waters, Steven G Deeks. (2006) Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 20:18, 2275-2283
CrossRef352
Giovanni Guaraldi. (2006) Cardiovascular complications in HIV-infected individuals. Current Opinion in HIV and AIDS 1:6, 507-513
CrossRef353
Dr Leonardo Calza, Roberto Manfredi, Francesco Chiodo. (2006) Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Therapeutic Patents 16:11, 1497-1516
CrossRef354
Roger Chou, Rongwei Fu, Laurie Hoyt Huffman, P Todd Korthuis. (2006) Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. The Lancet 368:9546, 1503-1515
CrossRef355
Graeme J Moyle, Caroline A Sabin, Jonathan Cartledge, Margaret Johnson, Edmund Wilkins, Duncan Churchill, Philip Hay, Ade Fakoya, Maurice Murphy, George Scullard, Clifford Leen, Geraldine Reilly. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20:16, 2043-2050
CrossRef356
V Reliquet, C Allavena, C Francois-Brunet, P Perre, V Bellein, M Garre, T May, F Souala, J-M Besnier, F Raffi. (2006) Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Medicine 7:7, 431-436
CrossRef357
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef358
Carlos-A Mestres, José M Miro. (2006) Cardiac surgery in human immunodeficiency virus positive patients. Indian Journal of Thoracic and Cardiovascular Surgery 22:4, 203-204
CrossRef359
M Floris-Moore, AA Howard, Y Lo, JH Arnsten, N Santoro, EE Schoenbaum. (2006) Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women. HIV Medicine 7:7, 421-430
CrossRef360
TR Glass, C Ungsedhapand, M Wolbers, R Weber, PL Vernazza, M Rickenbach, H Furrer, E Bernasconi, M Cavassini, B Hirschel, M Battegay, HC Bucher, . (2006) Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Medicine 7:6, 404-410
CrossRef361
F van Leth, DB Hall, JMA Lange, P Reiss. (2006) Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Medicine 7:6, 347-350
CrossRef362
Bruno R. Cotter. (2006) Endothelial dysfunction in HIV infection. Current HIV/AIDS Reports 3:3, 126-131
CrossRef363
Eoin Feeney, Eavan Muldoon, William G Powderly. (2006) Management of antiretroviral drug toxicity. Current Opinion in HIV and AIDS 1:5, 430-436
CrossRef364
W. M. LIJFERING, M. K. TEN KATE, H. G. SPRENGER, J. VAN DER MEER. (2006) Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. Journal of Thrombosis and Haemostasis 4:9, 1928-1930
CrossRef365
M Bickel, S Zangos, V Jacobi, T Lutz, G Knecht, F Goebel, S Staszewski, S Klauke. (2006) A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Medicine 7:6, 397-403
CrossRef366
Gregory J Dore, David A Cooper. (2006) HAART's first decade: success brings further challenges. The Lancet 368:9534, 427-428
CrossRef367
Blai Coll, Gerard Aragonés, Sandra Parra, Carlos Alonso-Villaverde, Lluis Masana. (2006) Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 20:12, 1675-1677
CrossRef368
Bo Jiang, Valeria Y. Hebert, James H. Zavecz, Tammy R. Dugas. (2006) Antiretrovirals Induce Direct Endothelial Dysfunction In Vivo. JAIDS Journal of Acquired Immune Deficiency Syndromes 42:4, 391-395
CrossRef369
Blai Coll, Jeroen P.H. van Wijk, Sandra Parra, Manuel Castro Cabezas, I.M. Hoepelman, Carlos Alonso-Villaverde, Eelco J.P. de Koning, Jordi Camps, Natalia Ferre, Ton J. Rabelink, Monica Tous, Jorge Joven. (2006) Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology 544:1-3, 104-110
CrossRef370
Huang, Laurence, Quartin, Andrew, Jones, Denis, Havlir, Diane V., . (2006) Intensive Care of Patients with HIV Infection. New England Journal of Medicine 355:2, 173-181
Full Text371
Vicente Estrada, María Teresa Martínez-Larrad, José Luis González-Sánchez, Noemí G.P. de Villar, Carina Zabena, Cristina Fernández, Manuel Serrano-Ríos. (2006) Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 55:7, 940-945
CrossRef372
AJ Busti, JP Tsikouris, MJ Peeters, SR Das, RM Canham, SM Abdullah, DM Margolis. (2006) A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Medicine 7:5, 317-322
CrossRef373
Rosario Palacios Muñoz, Jesús Santos González. (2006) Infección por el virus de la inmunodeficiencia humana: de Pneumocystis a estatinas. Medicina Clínica 127:7, 253-254
CrossRef374
Anna Soler, Elisabet Deig, Josep Guil, Marisa Rodríguez-Martín, Ana Guelar, Enric Pedrol. (2006) Eficacia y tolerancia de la atorvastatina en el tratamiento de la dislipemia secundaria a tratamiento antirretroviral. Medicina Clínica 127:7, 250-252
CrossRef375
David Rimland, Jodie L. Guest, Isabel Hern??ndez-Ramos, Carlos del Rio, N. Anh Le, W. Virgil Brown. (2006) Antiretroviral Therapy in HIV-Positive Women Is Associated With Increased Apolipoproteins and Total Cholesterol. JAIDS Journal of Acquired Immune Deficiency Syndromes 42:3, 307-313
CrossRef376
Rafik Samuel, Robert Bettiker, Byungse Suh. (2006) Antiretroviral therapy 2006: Pharmacology, applications, and special situations. Archives of Pharmacal Research 29:6, 431-458
CrossRef377
Steen B Haugaard. (2006) Toxic metabolic syndrome associated with HAART. Expert Opinion on Drug Metabolism & Toxicology 2:3, 429-445
CrossRef378
K. P. High, V. Valcour, R. Paul. (2006) HIV Infection and Dementia in Older Adults. Clinical Infectious Diseases 42:10, 1449-1454
CrossRef379
Susan S Kaplan, Charles B Hicks. (2006) Lopinavir/ritonavir: towards simplifying therapy in HIV infection. Future Virology 1:3, 293-304
CrossRef380
Cristina Mussini. (2006) Baseline HIV RNA and the when to start question: time to stop asking this question?. AIDS 20:8, 1197-1198
CrossRef381
Jessica R Grubb, Anne C Moorman, Rose K Baker, Henry Masur. (2006) The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 20:8, 1095-1107
CrossRef382
Pooja C. Oberai, Darshan Dalal, Lin Zhang, Cunlin Wang, Joseph Eustace, Rulan S. Parekh. (2006) Incidence of Atherosclerotic Cardiovascular Disease Among HIV Patients Receiving Dialysis. American Journal of Kidney Diseases 47:5, 848-855
CrossRef383
Anandi N. Sheth, Richard D. Moore, Kelly A. Gebo. (2006) Provision of General and HIV-Specific Health Maintenance in Middle Aged and Older Patients in an Urban HIV Clinic. AIDS Patient Care and STDs 20:5, 318-325
CrossRef384
Olga M. Klibanov, Mary van den Berg-Wolf, Margaret M. Kerper, Ellen M. Tedaldi. (2006) Elevations in Creatine Kinase and Hepatic Transaminases in an HIV-Positive Patient. Infectious Diseases in Clinical Practice 14:3, 181-184
CrossRef385
MG Law, N Friis-Moller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiebaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, JD Lundgren, . (2006) The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine 7:4, 218-230
CrossRef386
A. Solages, J. A. Vita, D. J. Thornton, J. Murray, T. Heeren, D. E. Craven, C. R. Horsburgh. (2006) Endothelial Function in HIV-Infected Persons. Clinical Infectious Diseases 42:9, 1325-1332
CrossRef387
Rosalind J. Carter, Jeffrey Wiener, Elaine J. Abrams, John Farley, Steven Nesheim, Paul Palumbo, Marc Bulterys. (2006) Dyslipidemia Among Perinatally HIV-Infected Children Enrolled in the PACTS-HOPE Cohort, 1999-2004. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:4, 453-460
CrossRef388
Rachael Jones, Brian Gazzard. (2006) HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors. Expert Review of Anti-infective Therapy 4:2, 303-312
CrossRef389
Patrick WG Mallon, John Miller, Jason C Kovacic, Julia Kent-Hughes, Richard Norris, Katherine Samaras, Michael P Feneley, David A Cooper, Andrew Carr. (2006) Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study. AIDS 20:7, 1003-1010
CrossRef390
Luc de Saint Martin, Olivier Vandhuick, Philippe Guillo, Véronique Bellein, Luc Bressollette, Nathalie Roudaut, Antonio Amaral, Elisabeth Pasquier. (2006) Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 185:2, 361-367
CrossRef391
Rakhi Kohli, Robert S. Klein, Ellie E. Schoenbaum, Kathryn Anastos, Howard Minkoff, Henry S. Sacks. (2006) Aging and HIV Infection. Journal of Urban Health 83:1, 31-42
CrossRef392
Stacy D. Fisher, Tracie L. Miller, Steven E. Lipshultz. (2006) Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 185:1, 1-11
CrossRef393
PN Kumar, A Rodriguez-French, MA Thompson, KT Tashima, D Averitt, PG Wannamaker, VC Williams, MS Shaefer, GE Pakes, KA Pappa, . (2006) A prospective, 96-week study of the impact of TrizivirR, CombivirR/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Medicine 7:2, 85-98
CrossRef394
Jeroen P.H. van Wijk, Eelco J.P. de Koning, Manuel Castro Cabezas, Jorge Joven, Jos op’t Roodt, Ton J. Rabelink, Andy M. Hoepelman. (2006) Functional and Structural Markers of Atherosclerosis in Human Immunodeficiency Virus-Infected Patients. Journal of the American College of Cardiology 47:6, 1117-1123
CrossRef395
Colleen Hadigan. (2006) Diabetes, insulin resistance, and HIV. Current Infectious Disease Reports 8:1, 69-75
CrossRef396
Rosa Polo, M.ª José Galindo, Esteban Martínez, Julia Álvarez, José Manuel Arévalo, Víctor Asensi, Dolores Cánoves, Emilia Cáncer, Julio Collazos, Vicente Estrada, Carmen Gómez-Candela, Susan Johnston, Jaime Locutura, José López-Aldeguer, Fernando Lozano, Celia Miralles, Agustín Muñoz-Sanz, Enrique Ortega, Javier Pascua, Enric Pedrol, Federico Pulido, Miguel San Martín, Jesús Sanz, Pompeyo Viciana, Lourdes Chamorro. (2006) Recomendaciones de GEAM/SPNS sobre el tratamiento de las alteraciones metabólicas y morfológicas en el paciente con infección por VIH. Enfermedades Infecciosas y Microbiología Clínica 24:2, 96-117
CrossRef397
P. E. Sax. (2006) Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 18:2, 149-157
CrossRef398
JAMES J. GLAZIER, J. RICHARD SPEARS, MELVIN C. MURPHY. (2006) Interventional Approach to Recurrent Myocardial Infarction in HIV-1 Infection. Journal of Interventional Cardiology 19:1, 93-98
CrossRef399
Marco Bongiovanni, Teresa Bini, Paola Cicconi, Simona Landonio, Paola Meraviglia, Letizia Testa, Antonio Di Biagio, Elisabetta Chiesa, Federica Tordato, Patrizia Biasi, Fulvio Adorni, Antonella D'Arminio Monforte. (2006) Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir. AIDS Research and Human Retroviruses 22:2, 132-138
CrossRef400
V. M. Carter, I. Woolley, D. Jolley, I. Nyulasi, A. Mijch, A. Dart. (2006) A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sexual Health 3:4, 287
CrossRef401
Kathy Petoumenos, Matthew G. Law. (2006) Risk factors and causes of death in the Australian HIV Observational Database. Sexual Health 3:2, 103
CrossRef402
Anna Suy, Esteban Martínez, Oriol Coll, Montserrat Lonca, Montserrat Palacio, Elisa de Lazzari, María Larrousse, Ana Milinkovic, Sandra Hernández, José L Blanco, Josep Mallolas, Agathe León, Juan A Vanrell, José M Gatell. (2006) Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 20:1, 59-66
CrossRef403
Sarangapany Jeganathan, Don Smith, Julian Gold. (2006) Early clinical experience with atazanavir in treatment-experienced patients. Sexual Health 3:1, 33
CrossRef404
Patrick W. G. Mallon. (2006) Antiretroviral Therapy and Dyslipidaemia: Unlocking the Code. PLoS Medicine 3:3, e85
CrossRef405
Magnus Gisslén, Jane Ahlqvist-Rastad, Jan Albert, Anders Blaxhult, Anna-Karin Hamberg, Stefan Lindbäck, Eric Sandström, Ingrid Uhnoo, Anders Sönnerborg, FOR THE SWEDISH CONSENSUS GROUP, Magnus Gisslén, Jane Ahlqvist-Rastad, Jan Albert, Anders Blaxhult, Anna-Karin Hamberg, Stefan Lindbäck, Eric Sandström, Ingrid Uhnoo, Anders Sönnerborg, FOR THE SWEDISH CONSENSUS GROUP. (2006) Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scandinavian Journal of Infectious Diseases 38:2, 86-103
CrossRef406
Alison Morris, Henry Masur, Laurence Huang. (2006) Current issues in critical care of the human immunodeficiency virus-infected patient*. Critical Care Medicine 34:1, 42-49
CrossRef407
Kelly A Gebo. (2006) HIV and Aging. Drugs & Aging 23:11, 897-913
CrossRef408
Kelly A Gebo, John A Fleishman, Richard D Moore. (2005) Hospitalizations for Metabolic Conditions, Opportunistic Infections, and Injection Drug Use Among HIV Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:5, 609-616
CrossRef409
Kelly A Gebo, Richard D Moore. (2005) Managing HIV infection in middle aged and older populations. Aging Health 1:3, 395-407
CrossRef410
Amanda Mocroft, Vincent Soriano, Jurgen Rockstroh, Peter Reiss, Ole Kirk, Stephane de Wit, Jose Gatell, Bonaventura Clotet, Andrew N Phillips, Jens D Lundgren. (2005) Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. AIDS 19:18, 2117-2125
CrossRef411
Patrick Robinson. (2005) Body Composition Changes in Patients with HIV. AJN, American Journal of Nursing 105:12, 69-72
CrossRef412
D. A. Wohl, H.-C. Tien, M. Busby, C. Cunningham, B. MacIntosh, S. Napravnik, E. Danan, K. Donovan, M. Hossenipour, R. J. Simpson. (2005) Randomized Study of the Safety and Efficacy of Fish Oil (Omega-3 Fatty Acid) Supplementation with Dietary and Exercise Counseling for the Treatment of Antiretroviral Therapy--Associated Hypertriglyceridemia. Clinical Infectious Diseases 41:10, 1498-1504
CrossRef413
Karolina M Zareba, Tracie L Miller, Steven E Lipshultz. (2005) Cardiovascular disease and toxicities related to HIV infection and its therapies. Expert Opinion on Drug Safety 4:6, 1017-1025
CrossRef414
MA Boyd, U Siangphoe, K Ruxrungtham, CJ Duncombe, M Stek, JMA Lange, DA Cooper, P Phanuphak. (2005) Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine 6:6, 410-420
CrossRef415
Blai Coll, Carlos Alonso-Villaverde. (2005) Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients. AIDS 19:16, 1936-1937
CrossRef416
Ranjababu Kulasegaram, Barry S. Peters, Anthony S. Wierzbicki. (2005) Dyslipidaemia and cardiovascular risk in HIV infection. Current Medical Research and Opinion 21:11, 1717-1725
CrossRef417
Michael P Dubé, Robert A Parker, Pablo Tebas, Steven K Grinspoon, Robert A Zackin, Gregory K Robbins, Ronenn Roubenoff, Robert W Shafer, David A Wininger, William A Meyer, Sally W Snyder, Kathleen Mulligan. (2005) Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19:16, 1807-1818
CrossRef418
C. Hadigan. (2005) Insulin Resistance among HIV-Infected Patients: Unraveling the Mechanism. Clinical Infectious Diseases 41:9, 1341-1342
CrossRef419
SD Shafran, LD Mashinter, SE Roberts. (2005) The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Medicine 6:6, 421-425
CrossRef420
R Jones, S Sawleshwarkar, C Michailidis, A Jackson, S Mandalia, J Stebbing, M Bower, M Nelson, BG Gazzard, GJ Moyle. (2005) Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Medicine 6:6, 396-402
CrossRef421
Blai Coll, Carlos Alonso-Villaverde, Sandra Parra, Manuel Montero, Monica Tous, Jorge Joven, Lluis Masana. (2005) The stromal derived factor-1 mutated allele (SDF1-3′A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. AIDS 19:16, 1877-1883
CrossRef422
Antonella Monforte, Marco Bongiovanni. (2005) Cerebrovascular disease in highly active antiretroviral therapy–treated individuals: Incidence and risk factors. Journal of NeuroVirology 11:0, 34-37
CrossRef423
P Mercie, R Thiebaut, V Aurillac-Lavignolle, JL Pellegrin, MC Yvorra-Vives, C Cipriano, D Neau, P Morlat, JM Ragnaud, M Dupon, F Bonnet, S Lawson-Ayayi, D Malvy, R Roudaut, F Dabis, . (2005) Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients*. HIV Medicine 6:6, 380-387
CrossRef424
Hammer, Scott M., . (2005) Management of Newly Diagnosed HIV Infection. New England Journal of Medicine 353:16, 1702-1710
Full Text425
I. Poizot-Martin, C. Marimoutou, M.P. Drogoul-Vey, F. Vion-Dury, V. Frixon-Marin, S. Benhaim, P. Poggi, J.A. Gastaut. (2005) Short Communication: Nelfinavir in HIV-HCV Coinfected Patients: A 24-Month Follow-Up in a Cohort of 82 Patients. AIDS Research and Human Retroviruses 21:10, 841-844
CrossRef426
Ard van Sighem, Sven Danner, Azra C Ghani, Luuk Gras, Roy M Anderson, Frank de Wolf. (2005) Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy Is Still Higher Than in Non-HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:2, 212-218
CrossRef427
K. H. Mayer, N. C. Casau. (2005) Perspective on HIV Infection and Aging: Emerging Research on the Horizon. Clinical Infectious Diseases 41:6, 855-863
CrossRef428
Ethan G. Leonard, Grace A. McComsey. (2005) Antiretroviral Therapy in HIV-Infected Children: The Metabolic Cost of Improved Survival. Infectious Disease Clinics of North America 19:3, 713-729
CrossRef429
Judith A. Aberg, Robert A. Zackin, Susan W. Brobst, Scott R. Evans, Beverly L. Alston, W. Keith Henry, Marshall J. Glesby, Francesca J. Torriani, Yijun Yang, Susan I. Owens, Carl J. Fichtenbaum. (2005) A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Research and Human Retroviruses 21:9, 757-767
CrossRef430
Obiamiwe C. Umeh, Judith S. Currier. (2005) Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Reports 2:3, 132-139
CrossRef431
A. Mocroft, A.N. Phillips, V. Soriano, J. Rockstroh, A. Blaxhult, C. Katlama, A. Boron-Kaczmarska, L. Viksna, O. Kirk, J.D. Lundgren. (2005) Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses 21:9, 743-752
CrossRef432
Marian E. Betz, Kelly A. Gebo, Ed Barber, Peter Sklar, John A. Fleishman, Erin D. Reilly, W Christopher Mathews. (2005) Patterns of Diagnoses in Hospital Admissions in a Multistate Cohort of HIV-Positive Adults in 2001. Medical Care 43:suppl, III-3-III-14
CrossRef433
D Rimland, JL Guest, I Hernandez, C del Rio, NA Le, WV Brown. (2005) Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Medicine 6:5, 326-333
CrossRef434
Gary Kalkut. (2005) Antiretroviral therapy: an update for the non-AIDS specialist. Current Opinion in Oncology 17:5, 479-484
CrossRef435
John A. Fleishman, Kelly A. Gebo, Erin D. Reilly, Richard Conviser, W Christopher Mathews, P Todd Korthuis, James Hellinger, Richard Rutstein, Philip Keiser, Haya Rubin, Richard D. Moore. (2005) Hospital and Outpatient Health Services Utilization Among HIV-Infected Adults in Care 2000???2002. Medical Care 43:suppl, III-40-III-52
CrossRef436
Daniel Fuster, Bonaventura Clotet. (2005) Review of atazanavir: a novel HIV protease inhibitor. Expert Opinion on Pharmacotherapy 6:9, 1565-1572
CrossRef437
Julian Falutz, Soraya Allas, Donald Kotler, Melanie Thompson, Polyxeni Koutkia, Jeanine Albu, Benoit Trottier, Jean-Pierre Routy, Pierre Cote, Thierry Abribat, Steven Grinspoon. (2005) A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19:12, 1279-1287
CrossRef438
Oriol Manuel, Rodolphe Thiébaut, Roger Darioli, Philip E Tarr. (2005) Treatment of dyslipidaemia in HIV-infected persons. Expert Opinion on Pharmacotherapy 6:10, 1619-1645
CrossRef439
S. K. Gupta. (2005) The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. Nephrology Dialysis Transplantation 20:10, 2237-2242
CrossRef440
Lukas E. Spieker, Bilgehan Karadag, Christian Binggeli, Roberto Corti. (2005) Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart and Vessels 20:4, 171-174
CrossRef441
F Boccara, S Ederhy, S Janower, N Benyounes, G Odi, A Cohen. (2005) Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. HIV Medicine 6:4, 240-244
CrossRef442
Michelle S. Cespedes, Judith A. Aberg. (2005) Cardiovascular and endothelial disease in HIV infection. Current Infectious Disease Reports 7:4, 309-315
CrossRef443
John G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, Jose M Vega, Amy Yang, Beverly L Alston, Susan W Brobst, Yoninah Segal, Judith A Aberg. (2005) Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:3, 307-312
CrossRef444
Leonardo Calza, Roberto Manfredi, Vincenzo Colangeli, Livia Tampellini, Teresa Sebastiani, Daria Pocaterra, Francesco Chiodo. (2005) Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19:10, 1051-1058
CrossRef445
Roland Tubiana, Guislaine Carcelain, Muriel Vray, Karine Gourlain, Cécile Dalban, Aziza Chermak, Claire Rabian, Daniel Vittecoq, Anne Simon, Elisabeth Bouvet, Raphaelle El Habib, Dominique Costagliola, Vincent Calvez, Brigitte Autran, Christine Katlama. (2005) Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23:34, 4292-4301
CrossRef446
Jonathan AC Sterne, Miguel A Hernán, Bruno Ledergerber, Kate Tilling, Rainer Weber, Pedram Sendi, Martin Rickenbach, James M Robins, Matthias Egger. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. The Lancet 366:9483, 378-384
CrossRef447
M Shah, K Tierney, B Adams-Huet, A Boonyavarakul, K Jacob, C Quittner, WL Dinges, D Peterson, A Garg. (2005) The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Medicine 6:4, 291-298
CrossRef448
Evan Wood, Robert S Hogg, P Richard Harrigan, Julio SG Montaner. (2005) When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. The Lancet Infectious Diseases 5:7, 407-414
CrossRef449
Judith S Currier, Michelle A Kendall, Robert Zackin, W Keith Henry, Beverly Alston-Smith, Francesca J Torriani, Jeff Schouten, Keith Mickelberg, Yanjie Li, Howard N Hodis. (2005) Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19:9, 927-933
CrossRef450
Marshall J. Glesby. (2005) Coronary heart disease in HIV-infected patients. Current HIV/AIDS Reports 2:2, 68-73
CrossRef451
Eric C Seaberg, Alvaro Muñoz, Ming Lu, Roger Detels, Joseph B Margolick, Sharon A Riddler, Carolyn M Williams, John P Phair. (2005) Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19:9, 953-960
CrossRef452
A. Mocroft, A.N. Phillips, V. Soriano, J. Rockstroh, A. Blaxhult, C. Katlama, A. Boron-Kaczmarska, L. Viksna, O. Kirk, J.D. Lundgren. (2005) Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses 21:6, 527-536
CrossRef453
José Tomás Ramos, María Isabel de José, Rosa Polo, Claudia Fortuny, María José Mellado, María Ángeles Muñoz-Fernández, José Beceiro, José María Bertrán, Cristina Calvo, Lourdes Chamorro, Luis Ciria, Sara Guillén, Raúl González-Montero, María Isabel González-Tomé, María Dolores Gurbindo, Pablo Martín-Fontelos, Jorge Martínez-Pérez, David Moreno, María Carmen Muñoz-Almagro, Antonio Mur, María Luisa Navarro, Carmen Otero, Pablo Rojo, Bárbara Rubio, Jesús Saavedra. (2005) Recomendaciones CEVIHP/SEIP/AEP/PNS respecto al tratamiento antirretroviral en niños y adolescentes infectados por el VIH. Enfermedades Infecciosas y Microbiología Clínica 23:5, 279-312
CrossRef454
Ann Danoff, Qiuhu Shi, Jessica Justman, Kathleen Mulligan, Nancy Hessol, Esther Robison, Dalian Lu, Tania Williams, Paula Wichienkuer, Kathryn Anastos. (2005) Oral Glucose Tolerance and Insulin Sensitivity Are Unaffected by HIV Infection or Antiretroviral Therapy in Overweight Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:1, 55-62
CrossRef455
M Bickel, V Rickerts, C Stephan, V Jacobi, C Rottmann, B Dauer, A Carlebach, A Thalhammer, V Miller, S Staszweski. (2005) The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load. HIV Medicine 6:3, 179-184
CrossRef456
Y Samarasinghe, C McIntosh, MD Feher. (2005) Diabetes and HIV: the role of a specialist clinic. Practical Diabetes International 22:4, 131-137
CrossRef457
Sara E Dolan, Colleen Hadigan, Kathleen M Killilea, Meghan P Sullivan, Linda Hemphill, Robert S Lees, David Schoenfeld, Steven Grinspoon. (2005) Increased Cardiovascular Disease Risk Indices in HIV-Infected Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:1, 44-54
CrossRef458
Martin Vogel, Jürgen K Rockstroh. (2005) Safety of lopinavir/ritonavir for the treatment of HIV-infection. Expert Opinion on Drug Safety 4:3, 403-420
CrossRef459
Rodolphe Thiébaut, Valérie Aurillac-Lavignolle, Fabrice Bonnet, Nagi Ibrahim, Claire Cipriano, Didier Neau, Michel Dupon, François Dabis, Patrick Mercié. (2005) Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999–2004. AIDS 19:7, 729-731
CrossRef460
Daniel S Kamin, Steven K Grinspoon. (2005) Cardiovascular disease in HIV-positive patients. AIDS 19:7, 641-652
CrossRef461
David Nolan, Peter Reiss, Simon Mallal. (2005) Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opinion on Drug Safety 4:2, 201-218
CrossRef462
A Richter, M Pladevall, R Manjunath, JE Lafata, H Xi, J Simpkins, I Brar, N Markowitz, UH Iloeje, W Irish. (2005) Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Medicine 6:2, 79-90
CrossRef463
Roberto Arduino. (2005) Editorial Commentary: CD4 Cell Count–Guided Treatment Interruption: Be Smart and Wait for More Evidence. Clinical Infectious Diseases 40:5, 735-737
CrossRef464
WM El-Sadr, CM Mullin, A Carr, C Gibert, C Rappoport, F Visnegarwala, C Grunfeld, SS Raghavan. (2005) Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Medicine 6:2, 114-121
CrossRef465
Maria Prins, Laurence Meyer, Nancy A Hessol. (2005) Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 19:4, 357-370
CrossRef466
Eric Daugas, Jean-Philippe Rougier, Gary Hill. (2005) HAART-related nephropathies in HIV-infected patients. Kidney International 67:2, 393-403
CrossRef467
James H Stein. (2005) Managing Cardiovascular Risk in Patients With HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 38:2, 115-123
CrossRef468
Judith C Shlay, Fehmida Visnegarwala, Glenn Bartsch, Jack Wang, Grace Peng, Wafaa M El-Sadr, Cynthia Gibert, Donald Kotler, Carl Grunfeld, Subhasree Raghavan. (2005) Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine. JAIDS Journal of Acquired Immune Deficiency Syndromes 38:2, 147-155
CrossRef469
Grinspoon, Steven, Carr, Andrew, . (2005) Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine 352:1, 48-62
Full Text470
André Carpentier, Bruce W. Patterson, Kristine D. Uffelman, Irving Salit, Gary F. Lewis. (2005) Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 178:1, 165-172
CrossRef471
N Bethuyne, P Lacor, JP Goldstein, FE Deuvaert. (2005) Coronary artery bypass grafting in a patient with HIV. HIV Medicine 6:1, 47-50
CrossRef472
UH Iloeje, Y Yuan, G L'Italien, J Mauskopf, SD Holmberg, AC Moorman, KC Wood, RD Moore. (2005) Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Medicine 6:1, 37-44
CrossRef473
A. Rudich, R. Ben-Romano, S. Etzion, N. Bashan. (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiologica Scandinavica 183:1, 75-88
CrossRef474
Francisco J. de Abajo. (2005) Improving Pharmacovigilance Beyond Spontaneous Reporting. International Journal of Pharmaceutical Medicine 19:4, 209-218
CrossRef475
Teresa García-Benayas, Francisco Blanco, Antonio Alcolea, Juan José De La Cruz, Juan González-Lahoz, Vincent Soriano. (2004) Short Communication: Benefits in the Lipid Profile after Substitution of Abacavir for Stavudine: A 48-Week Prospective Study. AIDS Research and Human Retroviruses 20:12, 1289-1292
CrossRef476
Anthony J. Busti, Ronald G. Hall, David M. Margolis. (2004) Atazanavir for the Treatment of Human Immunodeficiency Virus Infection. Pharmacotherapy 24:12, 1732-1747
CrossRef477
Tony Antoniou, Laura Park-Wyllie, Eleanor Boyle. (2004) A Comparison of Dyslipidemias Associated With Either Lopinavir/Ritonavir- or Indinavir/Ritonavir-Based Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 37:5, 1666-1667
CrossRef478
M. Bongiovanni, M. Pisacreta, M. Ortu, F. Tordato, R. Codemo, C. Gervasoni, R. Gornati, S. Trovati, R. Piolini, E. Chiesa, T. Porretta, T. Bini. (2004) Pseudoaneurysm of the Femoral Artery in a HIV-infected Man. European Journal of Vascular and Endovascular Surgery 28:4, 451-453
CrossRef479
J. Fredriksen, T. Ueland, E. Dyroy, B. Halvorsen, K. Melby, L. Melbye, B. S. Skalhegg, P. Bohov, J. Skorve, R. K. Berge, P. Aukrust, S. S. Froland. (2004) Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. European Journal of Clinical Investigation 34:10, 709-715
CrossRef480
Kelly A Gebo, Richard D Moore. (2004) Treatment of HIV infection in the older patient. Expert Review of Anti-infective Therapy 2:5, 733-743
CrossRef481
Paul E Sax, Princy Kumar. (2004) Tolerability and Safety of HIV Protease Inhibitors in Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes 37:1, 1111-1124
CrossRef482
Grace A McComsey, Ethan Leonard. (2004) Metabolic complications of HIV therapy in children. AIDS 18:13, 1753-1768
CrossRef483
(2004) Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18:13, 1811-1817
CrossRef484
Leonardo Calza, Roberto Manfredi, Francesco Chiodo. (2004) Insulin Resistance and Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy. Metabolic Syndrome and Related Disorders 2:4, 241-250
CrossRef485
I. J. Woolley, M. Larsen, S. Jones, M. E. Gahan, I. Jasenko, S. P. Johnsen, S. Wesselingh, A. Fuller, L. Ostergaard. (2004) Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-gamma assay, serology and PCR. Clinical Microbiology and Infection 10:9, 820-825
CrossRef486
Carlo Selmi, Susan R. Ross, Aftab A. Ansari, Pietro Invernizzi, Mauro Podda, Ross L. Coppel, M.Eric Gershwin. (2004) Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 127:2, 493-501
CrossRef487
M. T. Gerber, K. E. Mondy, K. E. Yarasheski, H. Drechsler, S. Claxton, J. Stoneman, D. DeMarco, W. G. Powderly, P. Tebas. (2004) Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy. Clinical Infectious Diseases 39:3, 419-425
CrossRef488
D. V. Havlir, S. D. O'Marro. (2004) Atazanavir: New Option for Treatment of HIV Infection. Clinical Infectious Diseases 38:11, 1599-1604
CrossRef489
TOMOSHIGE KINO, GEORGE P. CHROUSOS. (2004) Human Immunodeficiency Virus Type-1 Accessory Protein Vpr: A Causative Agent of the AIDS-Related Insulin Resistance/Lipodystrophy Syndrome?. Annals of the New York Academy of Sciences 1024:1, 153-167
CrossRef490
F Bonnet, E Balestre, R Thiebaut, P Mercie, M Dupon, P Morlat, F Dabis, . (2004) Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Medicine 5:3, 133-139
CrossRef491
Rajagopal V. Sekhar, Farook Jahoor, Henry J. Pownall, Christie M. Ballantyne, Ashok Balasubramanyam. (2004) Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Current Atherosclerosis Reports 6:3, 173-179
CrossRef492
Stebbing, Justin, Gazzard, Brian, Douek, Daniel C., . (2004) Where Does HIV Live?. New England Journal of Medicine 350:18, 1872-1880
Full Text493
Esteban Martínez, Pere Domingo, María J. Galindo, Ana Milinkovic, Juan A. Arroyo, Francisco Baldoví, María Larrousse, Agathe León, Elisa de Lazzari, José M. Gatell. (2004) Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavir‐Ritonavir. Clinical Infectious Diseases 38:7, 1017-1023
CrossRef494
Arati Wagh, Neil J Stone. (2004) Treatment of metabolic syndrome. Expert Review of Cardiovascular Therapy 2:2, 213-228
CrossRef495
Zelalem Temesgen, Francesca Cainelli, David Warnke, Janak Koirala. (2004) Initial antiretroviral therapy in chronically-infected HIV-positive adults. Expert Opinion on Pharmacotherapy 5:3, 595-612
CrossRef496
(2004) Trends in Rates of Myocardial Infarction among Patients with HIV. New England Journal of Medicine 350:7, 730-732
Full Text497
Susan D Driscoll, Gary E Meininger, Mark T Lareau, Sara E Dolan, Kathleen M Killilea, Colleen M Hadigan, Donald M Lloyd-Jones, Anne Klibanski, Walter R Frontera, Steven K Grinspoon. (2004) Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 18:3, 465-473
CrossRef498
Andrew Carr, Cassy Workman, Dianne Carey, Gary Rogers, Allison Martin, David Baker, Handan Wand, Matthew Law, Katherine Samaras, Sean Emery, David A Cooper. (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. The Lancet 363:9407, 429-438
CrossRef499
Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J. P. Kastelein, Mauro Schechter, Robert L. Murphy, Andrzej Horban, David B. Hall, Joep M. A. Lange, Peter Reiss. (2004) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine 1:1, e19
CrossRef500
Sklar, Peter, Masur, Henry, . (2003) HIV Infection and Cardiovascular Disease — Is There Really a Link?. New England Journal of Medicine 349:21, 2065-2067
Full Text
- Letters
